<article xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" article-type="review-article"><?properties open_access?><?DTDIdentifier.IdentifierValue -//NLM//DTD JATS (Z39.96) Journal Publishing DTD with OASIS Tables v1.0 20120330//EN?><?DTDIdentifier.IdentifierType public?><?SourceDTD.DTDName JATS-journalpublishing-oasis-article1.dtd?><?SourceDTD.Version 1.0?><?ConverterInfo.XSLTName jpoasis-nisons2nlmx2.xsl?><?ConverterInfo.Version 1?><front><journal-meta><journal-id journal-id-type="nlm-ta">RNA Biol</journal-id><journal-id journal-id-type="iso-abbrev">RNA Biol</journal-id><journal-id journal-id-type="publisher-id">KRNB</journal-id><journal-id journal-id-type="publisher-id">krnb20</journal-id><journal-title-group><journal-title>RNA Biology</journal-title></journal-title-group><issn pub-type="ppub">1547-6286</issn><issn pub-type="epub">1555-8584</issn><publisher><publisher-name>Taylor &amp; Francis</publisher-name></publisher></journal-meta><article-meta><article-id pub-id-type="pmcid">5207382</article-id><article-id pub-id-type="pmid">27715478</article-id><article-id pub-id-type="publisher-id">1236173</article-id><article-id pub-id-type="doi">10.1080/15476286.2016.1236173</article-id><article-categories><subj-group subj-group-type="heading"><subject>Review</subject></subj-group></article-categories><title-group><article-title><italic>In vitro</italic> evolution of chemically-modified nucleic acid aptamers: Pros and cons, and comprehensive selection strategies</article-title><alt-title alt-title-type="running-authors">F. LIPI ET&#160;AL.</alt-title><alt-title alt-title-type="running-title">RNA BIOLOGY</alt-title></title-group><contrib-group><contrib contrib-type="author"><contrib-id contrib-id-type="ORCID">0000-0002-0467-6409</contrib-id><name><surname>Lipi</surname><given-names>Farhana</given-names></name><xref ref-type="aff" rid="af0001"><sup>a</sup></xref></contrib><contrib contrib-type="author"><name><surname>Chen</surname><given-names>Suxiang</given-names></name><xref ref-type="aff" rid="af0001"><sup>a</sup></xref><xref ref-type="aff" rid="af0002"><sup>b</sup></xref></contrib><contrib contrib-type="author"><name><surname>Chakravarthy</surname><given-names>Madhuri</given-names></name><xref ref-type="aff" rid="af0001"><sup>a</sup></xref><xref ref-type="aff" rid="af0002"><sup>b</sup></xref></contrib><contrib contrib-type="author"><name><surname>Rakesh</surname><given-names>Shilpa</given-names></name><xref ref-type="aff" rid="af0001"><sup>a</sup></xref></contrib><contrib contrib-type="author"><name><surname>Veedu</surname><given-names>Rakesh N.</given-names></name><xref ref-type="aff" rid="af0001"><sup>a</sup></xref><xref ref-type="aff" rid="af0002"><sup>b</sup></xref><xref ref-type="corresp" rid="an0001"/></contrib><aff id="af0001"><label>a</label><institution>Western Australian Neuroscience Research Institute</institution>, Perth, <country>Australia</country></aff><aff id="af0002"><label>b</label><institution>Centre for Comparative Genomics, Murdoch University</institution>, Perth, <country>Australia</country></aff></contrib-group><author-notes><corresp id="an0001"><bold>CONTACT</bold> Rakesh N. Veedu <email xlink:href="r.veedu@murdoch.edu.au">r.veedu@murdoch.edu.au</email><institution>Centre for Comparative Genomics, Murdoch University</institution>, Perth, WA, <country>Australia</country>-6149</corresp></author-notes><pub-date pub-type="collection"><year>2016</year></pub-date><pub-date pub-type="epub"><day>7</day><month>10</month><year>2016</year></pub-date><pub-date pub-type="pmc-release"><day>7</day><month>10</month><year>2016</year></pub-date><!-- PMC Release delay is 0 months and 0 days and was based on the <pub-date pub-type="epub"/>. --><volume>13</volume><issue>12</issue><fpage seq="10">1232</fpage><lpage>1245</lpage><history><date date-type="received"><day>29</day><month>7</month><year>2016</year></date><date date-type="rev-recd"><day>6</day><month>9</month><year>2016</year></date><date date-type="accepted"><day>7</day><month>9</month><year>2016</year></date></history><permissions><!--<copyright-statement content-type="description"> &#x000a9; Farhana Lipi, Suxiang Chen, Madhuri Chakravarthy, Shilpa Rakesh, and Rakesh N. Veedu <copyright-statement>--><copyright-statement>&#169; 2016 The Author(s). Published with license by Taylor &amp; Francis Group, LLC</copyright-statement><copyright-year>2016</copyright-year><copyright-holder>The Author(s)</copyright-holder><license license-type="open-access" xlink:href="http://creativecommons.org/licenses/by-nc/3.0/"><license-p>This is an Open Access article distributed under the terms of the Creative Commons Attribution-Non-Commercial License (<ext-link ext-link-type="uri" xlink:href="http://creativecommons.org/licenses/by-nc/3.0/">http://creativecommons.org/licenses/by-nc/3.0/</ext-link>), which permits unrestricted non-commercial use, distribution, and reproduction in any medium, provided the original work is properly cited. The moral rights of the named author(s) have been asserted.</license-p></license></permissions><self-uri content-type="pdf" xlink:href="krnb-13-12-1236173.pdf"/><abstract><title>ABSTRACT</title><p>Nucleic acid aptamers are single-stranded DNA or RNA oligonucleotide sequences that bind to a specific target molecule with high affinity and specificity through their ability to adopt 3-dimensional structure in solution. Aptamers have huge potential as targeted therapeutics, diagnostics, delivery agents and as biosensors. However, aptamers composed of natural nucleotide monomers are quickly degraded <italic>in vivo</italic> and show poor pharmacodynamic properties. To overcome this, chemically-modified nucleic acid aptamers are developed by incorporating modified nucleotides after or during the selection process by Systematic Evolution of Ligands by EXponential enrichment (SELEX). This review will discuss the development of chemically-modified aptamers and provide the pros and cons, and new insights on <italic>in vitro</italic> aptamer selection strategies by using chemically-modified nucleic acid libraries.</p></abstract><kwd-group kwd-group-type="author"><title>KEYWORDS</title><kwd>Aptamers</kwd><kwd>chemical antibodies</kwd><kwd>chemically-modified aptamers</kwd><kwd><italic>in vitro</italic> selection</kwd><kwd>modified nucleotides</kwd><kwd>nucleic acid ligands</kwd><kwd>SELEX</kwd></kwd-group><counts><fig-count count="5"/><table-count count="0"/><ref-count count="113"/><page-count count="14"/></counts></article-meta></front><body><sec><title>Abbreviations</title><p>
<def-list><def-item><term>SELEX</term><def><p>Systematic Evolution of Ligands by EXponential enrichment</p></def></def-item><def-item><term>US FDA</term><def><p>United States Food and Drug Administration</p></def></def-item><def-item><term>AMD</term><def><p>Age-related macular degeneration</p></def></def-item><def-item><term>VEGF</term><def><p>Vascular endothelial growth factor protein, 2&#8242;-NH<sub>2</sub>, 2&#8242;-Amino</p></def></def-item><def-item><term>2&#8242;-OH</term><def><p>2&#8242;-Hydroxyl</p></def></def-item><def-item><term>K<sub>d</sub></term><def><p>Equilibrium dissociation constant</p></def></def-item><def-item><term>2&#8242;-OMe</term><def><p>2&#8242;-O-Methyl</p></def></def-item><def-item><term>Bfgf</term><def><p>Basic fibroblast growth factor</p></def></def-item><def-item><term>2&#8242;-F</term><def><p>2&#8242;-Fluoro</p></def></def-item><def-item><term>PSMA</term><def><p>Prostate specific membrane antigen</p></def></def-item><def-item><term>IFN-&#947;</term><def><p>Interferon-gamma</p></def></def-item><def-item><term>KGF</term><def><p>Keratinocyte growth factor</p></def></def-item><def-item><term>4&#8242;-S</term><def><p>4&#8242;-Thio</p></def></def-item><def-item><term>2&#8242;-FANA</term><def><p>2&#8242;-Fluroarabino nucleic acid</p></def></def-item><def-item><term>HNA</term><def><p>1,5-Anhydro hexitol nucleic acid</p></def></def-item><def-item><term>TAR</term><def><p>transactivation responsive element</p></def></def-item><def-item><term>TNA</term><def><p>Threose nucleic acid</p></def></def-item><def-item><term>LNA</term><def><p>Locked nucleic acid</p></def></def-item><def-item><term>SOMAmers</term><def><p>Slow Off-rate Modified Aptamers</p></def></def-item></def-list></p></sec><sec sec-type="intro" id="s0001"><title>Introduction</title><p>Nucleic acid aptamer technology has attracted considerable attention in recent years in light of their widespread applications in therapeutic development, targeted drug delivery, bio-sensing and accurate molecular imaging. Aptamers are short single-stranded DNA or RNA oligonucleotides with unique 3-dimensional shape that can bind to their specific target with very high affinity and specificity.<xref rid="cit0001" ref-type="bibr"><sup>1-5</sup></xref> Aptamers are generally developed from a large pool of oligonucleotide libraries containing approximately 10<sup>14</sup> members by a reiterative process referred to as SELEX which involves selection, separation and enrichment steps (<xref ref-type="fig" rid="f0001">Fig.&#160;1</xref>).<xref rid="cit0006" ref-type="bibr"><sup>6,7</sup></xref> Till now, antibodies have been widely used for target specific molecular recognition.<xref rid="cit0008" ref-type="bibr"><sup>8</sup></xref> However, compared to antibody-based technologies, aptamers may possess a number of advantages including easy laboratory production <italic>in vitro</italic> effectively eliminating the use of live animals, no batch to batch variation, low or no immunogenicity, freedom to introduce multiple chemistries during synthesis without losing the affinity and specificity, small size that allows faster tissue penetration, ability to reverse target binding interactions using its complementary antidote sequence, significantly longer shelf-life and low cost. In 2004, an aptamer drug Macugen (Pegaptanib Sodium) was approved by United States Food and Drug Administration (US FDA) for the treatment of neovascular age-related macular degeneration (AMD) by targeting vascular endothelial growth factor protein 165 (VEGF<sub>165</sub>).<xref rid="cit0009" ref-type="bibr"><sup>9,10</sup></xref> Currently, a number of aptamer-based therapeutic candidates are in preclinical development and in different stages of clinical trials.<xref rid="cit0011" ref-type="bibr"><sup>11</sup></xref>
<fig id="f0001" orientation="portrait" position="float"><label>Figure 1.</label><caption><p>Schematic illustration of the SELEX and post-SELEX methods for developing aptamers.</p></caption><graphic specific-use="web-only" xlink:href="krnb-13-12-1236173-g001"/></fig>
</p><p>Typically, aptamers are developed with naturally occurring nucleotides. However, aptamers composed of natural nucleotide monomers are not suitable for theranostic applications as they possess very poor resistance to enzymatic degradation and show decreased binding affinity, rendering poor pharmacokinetic properties. To circumvent these shortcomings, aptamers containing chemically-modified nucleotide analogs with high stability against nucleases are normally used. Early examples of modified aptamers were primarily produced by post-SELEX-based approach. In this process, the aptamers were first isolated using natural RNA or DNA random sequences by SELEX method and then modified as per demand on affinity, stability and functionality. For this purpose, appropriate chemically-modified nucleotides are systematically incorporated into an existing DNA/RNA aptamer during solid-phase oligonucleotide synthesis. Generally, a web-based secondary structure prediction algorithm (e.g. mfold,<xref rid="cit0012" ref-type="bibr"><sup>12</sup></xref> RNAfold<xref rid="cit0013" ref-type="bibr"><sup>13</sup></xref>) is used as a tool to assist with the positioning of chemically-modified nucleotides and to truncate the overall size of the selected aptamers during chemical synthesis. Such chemically-fabricated aptamer variants are then tested for binding affinity, and the best candidates are used for further analysis and down-stream applications <italic>in vitro</italic> and <italic>in vivo</italic>. Evolution of chemically-modified aptamers would be a far more powerful approach to develop modified aptamers as this could generate aptamers with unique structures and with even shorter libraries.</p></sec><sec id="s0002"><title>Evolution of chemically-modified aptamers</title><p>A large repertoire of chemically-modified nucleotide analogs with remarkable biophysical properties have been developed in recent years and a few papers have reviewed the use of these chemically-modified nucleotides in the generation of aptamers and nucleic acids with enzymatic activity including DNAzymes and ribozymes.<xref rid="cit0014" ref-type="bibr"><sup>14-18</sup></xref> But, their applicability in <italic>de novo</italic> evolution of aptamers via SELEX methodologies are rather impeded by poor or lack of enzymatic recognition capabilities. Conventional selection methodologies involve multiple enzymatic steps that are required to amplify and regenerate chemically-modified nucleotide-containing libraries. Some sugar-modified nucleotides are reported to tolerate few commercially available DNA or RNA polymerases,<xref rid="cit0019" ref-type="bibr"><sup>19</sup></xref> making them promising candidates for aptamer selection. However, it is worth mentioning that the level of enzymatic recognition capabilities of the reported modified nucleotides varies depending on the specific chemical modification. Still, the substrate properties of a number of other promising analogs have not been reported which might be due to the lack of enzymatic recognition. One option is to evolve an enzyme specific to the modified nucleotide, and there are reports of successful aptamer selection using engineered enzymes for chemically-modified nucleotides.<xref rid="cit0020" ref-type="bibr"><sup>20,21</sup></xref> An overview of possible strategies that can be applied for selecting chemically-modified aptamers are outlined below (<xref ref-type="fig" rid="f0002">Fig.&#160;2</xref>).
<fig id="f0002" orientation="portrait" position="float"><label>Figure 2.</label><caption><p>The construction of oligonucleotide libraries for developing chemically modified libraries.</p></caption><graphic specific-use="web-only" xlink:href="krnb-13-12-1236173-g002"/></fig>
</p></sec><sec id="s0003"><title>Generation of chemically-modified libraries and selection strategies</title><p>Starting oligonucleotide libraries containing the desired chemically-modified nucleotide or a combination of different modifications can be chemically synthesized using an oligonucleotide synthesizer via standard phosphoramidite chemistry. Another approach could be to synthesize normal DNA library which subsequently can be converted to a chemically-modified library by following enzymatic protocols involving PCR and/or <italic>in vitro</italic> transcription reactions with modified nucleotide triphosphates using the specific polymerase which could also be used in subsequent amplification/regeneration steps of multiple selection rounds. Synthetic chemically-modified libraries can be constructed by incorporating the modified nucleotides in the randomized region or in the primer-binding region.</p></sec><sec id="s0004"><title>Library with modified random region</title><p>Modified nucleotides can be incorporated as mixmers together with natural nucleotide monomers or as fully modified in the random region to furnish a chemically-modified oligonucleotide library for aptamer selection. However, the libraries containing fully modified random region with all four modified nucleotide bases may be limited to use in one-step aptamer selection-based methodologies. This is mainly because the selected aptamer candidates are regenerated using triphosphate derivatives of the corresponding modified nucleotides, but during an enzymatic synthesis process, the primer-binding region will also be modified with the same modified nucleotides contrary to the starting library design. In SELEX to allow maximum base variations of the chemically-modified nucleotides (good substrates of specific enzymes) in the random region, the nucleotide bases can be mixed with one, two or three modified nucleotide bases of the same or different nucleotide analogs in combination with the natural counterparts. But, depending on the number of modified nucleotide bases in the randomized region, the primer-binding region needs to be adjusted with the base composition of unmodified nucleotides. In this approach, where nucleotide mixmers are randomized, it is difficult to locate the positioning of modified nucleotide analogs, and if the library is constructed with successive stretch of modified nucleotides it may be hard for the polymerases to regenerate these particular sequences for subsequent selection rounds.</p><p>Another design approach could be to fix the positioning of modified nucleotides in the random region, which will assist to keep track of the positioning of modified nucleotides after sequencing. But, this could limit the pool diversity to some extent, however, it is worthwhile to perform selection since some chemical modifications could generate unique shapes and enhance target binding affinity. It is best to limit up to two fixed modifications that could be incorporated individually at different positions or as a mixture at the same positions allowing two nucleotide variations. Again, the primer-binding region needs to be constructed only with the unmodified natural nucleotide bases (avoiding similar base counterparts of the chemically-modified nucleotides) to regenerate the selected aptamer candidates for use in the subsequent selection rounds. During the sequence alignment after sequencing, only those candidates that maintain the initial library design need to be considered for further analysis and chemical synthesis.</p><sec id="s0004-0001"><title>Library with modified primer-binding region</title><p>For some modified nucleotide analogs that offer potential biophysical properties, enzymatic recognition may be difficult limiting their application in aptamer selection using conventional SELEX method. But, such modifications can still be used in aptamer selection using a library with one of the primer-binding regions containing the desired chemically-modified nucleotides, and the other region with all four natural nucleotide monomers. This will essentially eliminate the need of an enzymatic recognition of modified nucleotides as a synthetic primer sequence with the chemical modifications can be used during the enrichment steps. But, the protocol may be limited to DNA-based oligonucleotides. This approach may not fit very well in line to the concept of aptamer selection where it is speculated that the randomized region would promote the formation of target-binding motifs due to high sequence variability. But, one cannot ignore the fact that a part of the primer-binding region also plays a role in the folding pattern of the binding aptamers in majority of the cases. On this ground, aptamer selection using a library with chemically-modified primer-binding regions can be well justified, and can be used as an alternate approach. This method has been successfully applied for generating LNA-modified aptamers.<xref rid="cit0022" ref-type="bibr"><sup>22,23</sup></xref></p></sec><sec id="s0004-0002"><title>&#8734;-aptamer library</title><p>Aptamer selections can also be performed using a library containing infinite range (<bold>&#8734;</bold>) of modified nucleotides with non-natural structural chemistries of the nucleobase, sugar and phosphate backbone. Libraries containing infinite nucleotides could come with diverse range of chemistries bearing positive charges, hydrophobic groups, phosphorothioates, amino acids etc. that could improve and enhance the target binding interactions and nuclease resistance. Such libraries are mainly suitable for one-step selection protocols.<xref rid="cit0024" ref-type="bibr"><sup>24-27</sup></xref>
<bold>&#8734;</bold>-nucleotides can be best positioned in the randomized regions. During synthesis, <bold>&#8734;</bold>-nucleotides of all four bases can also be mixed with their natural counterparts.</p></sec></sec><sec id="s0005"><title>Aptamer selection using sugar-modified nucleotides</title><p>Modifications of sugars will result in libraries with a greater functional diversity and can form stable aptamers with unique shapes. Sugar modifications could allow screening of ligands that bind with greater affinity to their targets than their unmodified counterparts. These unnatural modifications are less likely to be recognized by nucleases, making them more stable in serum. Most frequently, chemical modifications are introduced at the 2&#8242;-position of the nucleotide for increased nuclease resistance, and binding affinity. The SELEX evolution of various sugar- modified nucleotide (<xref ref-type="fig" rid="f0003">Fig.&#160;3</xref>) containing aptamers against different targets, their binding affinities and stabilities are described below. <xref ref-type="table" rid="t0001">Table&#160;1</xref> shows an overview of sugar-modified aptamer development in recent years.
<fig id="f0003" orientation="portrait" position="float"><label>Figure 3.</label><caption><p>Structures of various sugar-modified nucleotides used in aptamer selection by SELEX methodologies.</p></caption><graphic xlink:href="krnb-13-12-1236173-g003"/></fig>
<table-wrap id="t0001" orientation="portrait" position="float"><label>Table 1.</label><caption><p>Aptamers selected from sugar-modified DNA/RNA libraries and the binding affinity of aptamers to their targets.</p></caption><!--OASIS TABLE HERE--></table-wrap>
</p><sec id="s0005-0001"><title>2&#8242;-Amino (2&#8242;-NH<sub>2</sub>) modified aptamers</title><p>Aptamers have been selected from libraries where the 2&#8242;-hydroxyl (2&#8242;-OH) group of the pyrimidine is replaced by a NH<sub>2</sub> group. A modified aptamer was screened from a 2&#8242;-NH<sub>2</sub> -modified RNA library involving 2&#8242;-NH<sub>2</sub>-UTP and 2&#8242;-NH<sub>2</sub>-CTP replacing unmodified UTP and CTP during enrichment steps, specific to the human neutrophil elastase using nitrocellulose filter binding assay.<xref rid="cit0028" ref-type="bibr"><sup>28</sup></xref> The selected aptamers showed high affinity to the target with the equilibrium dissociation constant (K<sub>d</sub>) in the range of 7&#8211;30&#160;nM which is much lower than that of the unmodified RNA aptamer (K<sub>d</sub> &gt; 1&#160;&#181;M).<xref rid="cit0028" ref-type="bibr"><sup>28</sup></xref> These aptamers were found to be very selective to human neutrophil elastase.<xref rid="cit0028" ref-type="bibr"><sup>28</sup></xref> These modified RNA aptamers also improved nuclease resistance, with an extended half-life (20&#160;h and 9&#160;h in serum and urine respectively) than the unmodified aptamer (degraded in less than 8 and 5 mins in serum and urine respectively).<xref rid="cit0028" ref-type="bibr"><sup>28</sup></xref> Another 2&#8242;-NH<sub>2</sub>-pyrimidine-modified RNA aptamer was developed against VPF/VEGF by SELEX process.<xref rid="cit0029" ref-type="bibr"><sup>29</sup></xref> The affinity was measured through nitrocellulose filter binding assay and one aptamer NX-178 had a K<sub>d</sub> of 2.4&#160;nM, with an increased half-life in urine (17&#160;h).<xref rid="cit0029" ref-type="bibr"><sup>29</sup></xref> Interestingly the introduction of a 2&#8242;-O-Methyl (2&#8242;-OMe) nucleotide post-SELEX further increased the binding affinity to K<sub>d</sub> = 0.14&#160;nM and half-life in urine to 31&#160;h.<xref rid="cit0029" ref-type="bibr"><sup>29</sup></xref> This study suggests that the affinity and nuclease resistance of the RNA modified aptamers developed by SELEX methodology can be further improved by post-SELEX modification. In another study, <italic>Beaudry et&#160;al.</italic> developed a 2&#8242;-NH<sub>2</sub> pyrimidine-modified ribozyme which was identified by affinity column-based SELEX.<xref rid="cit0030" ref-type="bibr"><sup>30</sup></xref> The selected aptamer had a half-life of 16&#160;h in human serum, whereas the unmodified counterpart degraded in serum in just 5 mins.<xref rid="cit0030" ref-type="bibr"><sup>30</sup></xref>
<italic>Jellinek et&#160;al.</italic> developed a different 2&#8242;-NH<sub>2</sub> pyrimidine-modified RNA aptamer, selected through nitrocellulose membrane filter binding assay specific to basic fibroblast growth factor (bFGF).<xref rid="cit0031" ref-type="bibr"><sup>31</sup></xref> The identified aptamer m21A bound to bFGF with high binding affinity (K<sub>d</sub> = 0.35&#160;nM).<xref rid="cit0031" ref-type="bibr"><sup>31</sup></xref> The stability of this aptamer in serum is 100 fold higher than the natural RNA aptamer.<xref rid="cit0031" ref-type="bibr"><sup>31</sup></xref> In another study, <italic>Bugaut et&#160;al.</italic> used an interesting methodology whereby SELEX and dynamic combinatorial chemistry were combined to select conjugated RNA aptamers against MiniTAR by magnetic bead immobilisation using a 2&#8242;-NH<sub>2-</sub> modified RNA library. The resulting conjugated aptamers developed bound to MiniTAR with high affinity (K<sub>d</sub> = 26&#8211;47&#160;nM).<xref rid="cit0032" ref-type="bibr"><sup>32</sup></xref></p></sec><sec id="s0005-0002"><title>2&#8242;-fluoro (2&#8242;-F) modified aptamers</title><p><italic>Ruckman et&#160;al.</italic> developed an RNA aptamer specific to VEGF<sub>165</sub>&#160;isoform by nitrocellulose filter binding assay using 2&#8242;-F modified RNA libraries.<xref rid="cit0033" ref-type="bibr"><sup>33</sup></xref> Most of the selected 2&#8242;-F RNA aptamers had affinities for VEGF<sub>165</sub>&#160;in the pM range (aptamer with the lowest affinities had a K<sub>d</sub> value of 2 pM).<xref rid="cit0033" ref-type="bibr"><sup>33</sup></xref> This candidate aptamer after further chemical modifications has been approved by the US FDA for the treatment of AMD. <italic>Lupold et&#160;al.</italic> developed another 2&#8242;-F modified RNA aptamer A10, targeting prostate specific membrane antigen (PSMA), cell surface receptors expressed on prostate cancer cells by SELEX using magnetic bead separation-based method.<xref rid="cit0034" ref-type="bibr"><sup>34</sup></xref> The aptamer A10 bound to PSMA with a K<sub>d</sub> of 11.9&#160;nM in LNCaP cells.<xref rid="cit0034" ref-type="bibr"><sup>34</sup></xref> This was later used to link siRNA to form aptamer-siRNA chimeras that allowed targeted delivery of siRNA to cells expressing PSMA wherein the siRNA reduced the expression of two survival genes, Polo-like kinase 1 and B-cell lymphoma 2.<xref rid="cit0034" ref-type="bibr"><sup>34,35</sup></xref> In another study, <italic>Biesecker et&#160;al.</italic> developed another aptamer against human complement C5 component using 2&#8242;-F pyrimidine-modified RNA libraries by nitrocellulose membrane filter binding assay.<xref rid="cit0036" ref-type="bibr"><sup>36</sup></xref> The aptamers generated had K<sub>d</sub> of between 20&#8211;40&#160;nM and this was further improved by a second biased SELEX experiment where the generated aptamers had a K<sub>d</sub> of 2&#8211;5&#160;nM.<xref rid="cit0036" ref-type="bibr"><sup>36</sup></xref> The aptamers generated were able to bind to human complement C5 component with high affinity and were able to inhibit its activity in human serum with high stability.<xref rid="cit0036" ref-type="bibr"><sup>36</sup></xref>
<italic>Rusconi et&#160;al.</italic> developed 2&#8242;-F modified aptamers for Factor II, Factor VII, Factor IX and Factor X through nitrocellulose membrane filter binding assay.<xref rid="cit0037" ref-type="bibr"><sup>37,38</sup></xref> By this approach a RNA aptamer was identified against Factor IXa with the highest affinity (K<sub>d</sub> of 0.64&#160;nM), and was a potent anticoagulant.<xref rid="cit0038" ref-type="bibr"><sup>38</sup></xref> Another aptamer generated against Factor IX had a K<sub>d</sub> of 364 pM.<xref rid="cit0037" ref-type="bibr"><sup>37</sup></xref>
<italic>Lamberti et&#160;al.</italic> developed an aptamer against Cancer Antigen 125 by magnetic bead immobilisation using a 2&#8242;-F modified RNA library.<xref rid="cit0039" ref-type="bibr"><sup>39</sup></xref> Of the two RNA aptamers isolated, CA125.1 had a K<sub>d</sub> of 4.15&#160;nM and can be developed further for use as a diagnostic tool.<xref rid="cit0039" ref-type="bibr"><sup>39</sup></xref></p></sec><sec id="s0005-0003"><title>Comparison of 2&#8242;-F and 2&#8242;-NH<sub>2</sub> modifications</title><p>Various studies indicate that both 2&#8242;-F and 2&#8242;-NH<sub>2</sub> modifications increase the nuclease resistance and binding affinity of aptamers toward their targets. There are a few studies comparing the two modifications to validate which modification was more powerful. <italic>Kubik et&#160;al.</italic> reported an aptamer that bound to interferon-gamma (IFN-&#947;) which was screened from RNA libraries modified at the 2&#8242;-position of pyrimidine nucleotides with F, NH<sub>2</sub>, or a mixture of F and NH<sub>2</sub> (2&#8242;-F/NH<sub>2</sub>) groups using nitrocellulose filter binding assay.<xref rid="cit0040" ref-type="bibr"><sup>40</sup></xref> The binding affinity of the modified aptamers to IFN-&#947; differed depending on the sugar modifications.<xref rid="cit0040" ref-type="bibr"><sup>40</sup></xref> 2&#8242;-NH<sub>2</sub> modified aptamers had the highest binding affinity to IFN-&#947; with a K<sub>d</sub> of 1.8&#160;nM, whereas the 2&#8242;-F modified aptamers with the highest binding affinity had a K<sub>d</sub> of 6.8&#160;nM and the aptamers containing 2&#8242;-F/NH<sub>2</sub> mixture had a K<sub>d</sub> of 106&#160;nM.<xref rid="cit0040" ref-type="bibr"><sup>40</sup></xref> The half-lives of these aptamers were measured through their stability in human serum, where 2&#8242;-NH<sub>2</sub> modified aptamer had a half-life of 80&#160;h, 2&#8242;-F modified aptamers had a half-life of 6&#160;h and the mixed 2&#8242;F/NH<sub>2</sub> modified aptamers had a half-life of 48&#160;h.<xref rid="cit0040" ref-type="bibr"><sup>40</sup></xref> However, all three were more nuclease-resistant than the unmodified aptamer which had a half-life of 20&#160;s in human serum.<xref rid="cit0040" ref-type="bibr"><sup>40</sup></xref> 2&#8242;-NH<sub>2</sub> modified aptamers seemed to confer the highest binding affinity to IFN-&#947; and nuclease resistance in human serum.<xref rid="cit0040" ref-type="bibr"><sup>40</sup></xref> 2&#8242;-NH<sub>2</sub> aptamer also inhibited IFN-&#947; binding to its receptor on A549 human lung carcinoma cells with an ID<sub>50</sub> of 10&#160;nM.<xref rid="cit0040" ref-type="bibr"><sup>40</sup></xref> Another study by <italic>Pagratis et&#160;al.</italic> suggested that 2&#8242;-F modified aptamers improved the binding affinity compared to the 2&#8242;-NH<sub>2</sub> modified aptamers.<xref rid="cit0041" ref-type="bibr"><sup>41</sup></xref> In this study, aptamers have been selected successfully from libraries containing 2&#8242;-NH<sub>2</sub> and 2&#8242;-F modified pyrimidines by nitrocellulose filter binding assay and compared the affinities of the two different aptamer variants to keratinocyte growth factor (KGF).<xref rid="cit0041" ref-type="bibr"><sup>41</sup></xref> The best 2&#8242;-F modified aptamer 14F bound to KGF with a higher affinity (K<sub>d</sub> = 0.3&#8211;3 pM) than the best 2&#8242;-NH<sub>2</sub> modified aptamer (K<sub>d</sub> = 0.4&#160;nM).<xref rid="cit0041" ref-type="bibr"><sup>41</sup></xref> 2&#8242;-F modified aptamers (6F and 14F) inhibited KGF binding to their receptor in PC3 cells with a K<sub>i</sub> of 100 and 200 pM respectively and had a much higher inhibitory activity than the 2&#8242;-NH<sub>2</sub> modified variants, 14N and 29N (K<sub>i</sub> = 1.4&#160;nM).<xref rid="cit0041" ref-type="bibr"><sup>41</sup></xref> Although if 2&#8242;-F or 2&#8242;-NH<sub>2</sub> modification is more powerful is arguable the use of 2&#8242;-NH<sub>2</sub> modifications result in problems in solid-phase synthesis and the ribose sugar adopting an unfavorable conformation which has resulted in the reduced use of 2&#8242;-NH<sub>2</sub>.</p></sec><sec id="s0005-0004"><title>2&#8242;-OMe modifications:</title><p>2&#8242;-OMe modification involves the replacement of the 2&#8242;-OH group of the nucleotide with a methoxy group. 2&#8242;-OMe is a common sugar modification that has been used post-SELEX to generate aptamers with high nuclease resistance. <italic>Burmeister et&#160;al.</italic> developed an aptamer against VEGF from oligonucleotide libraries modified with 2&#8242;-OMe adenine and guanines by electrophoretic mobility shift assay.<xref rid="cit0042" ref-type="bibr"><sup>42</sup></xref> The selected aptamer candidate, ARC245 had a K<sub>d</sub> of 2&#160;nM, however this is lower than Macugen, the FDA approved aptamer drug targeting VEGF (K<sub>d</sub> = 50 pM).<xref rid="cit0042" ref-type="bibr"><sup>42</sup></xref> ARC245 showed inhibition of VEGF binding to VEGF receptor in 293 cells at 10&#160;nM concentrations and was also highly stable in serum for up to 96&#160;h.<xref rid="cit0042" ref-type="bibr"><sup>42</sup></xref>
<italic>Burmeister et&#160;al.</italic> also screened aptamers comprising 2&#8242;-OMe pyrimidines by the SELEX process to multiple protein targets including thrombin and interleukin-23, using proteins immobilized on a 96-well plate and nitrocellulose filter binding assay.<xref rid="cit0043" ref-type="bibr"><sup>43</sup></xref> The identified aptamers targeting interleukin-23 had a K<sub>d</sub> of 8.4&#160;nM while the aptamer targeting thrombin had a K<sub>d</sub> of 26&#160;nM.<xref rid="cit0043" ref-type="bibr"><sup>43</sup></xref>
<italic>Waters et&#160;al.</italic> developed 2&#8242;-OMe modified aptamers, ARC19499 and ARC17480 against tissue factor pathway inhibitor by nitrocellulose filter binding using a 2&#8242;-OMe modified library.<xref rid="cit0044" ref-type="bibr"><sup>44</sup></xref> ARC17480 bound to the tissue factor pathway inhibitor with a K<sub>d</sub> of 2.8&#160;nM, however as ARC19499 was not viable in experiments requiring radiolabelling a competition-binding experiment showed that ARC19499 competed with radiolabelled ARC17480 with an IC<sub>50</sub> of 17.9&#160;nM.<xref rid="cit0044" ref-type="bibr"><sup>44</sup></xref> 2&#8242;-OMe incorporation into libraries and using these modified libraries for SELEX is hard due to lack of enzymes that are capable of recognizing these 2&#8242;-OMe modified bases. However, recently polymersases have been evolved that accept 2&#8242;-OMe modified triphosphates which would allow generation of additional 2&#8242;-OMe modified aptamers.<xref rid="cit0021" ref-type="bibr"><sup>21,45-49</sup></xref></p></sec><sec id="s0005-0005"><title>4&#8242;-Thio (4&#8242;-S) modifications</title><p>4&#8242;-S modifications had a sulfur atom at the 4&#8242;-position of the sugar moiety. <italic>Kato et&#160;al.</italic> developed a 4&#8242;-S modified RNA aptamer that bound to human &#945;-thrombin by nitrocellulose filter binding assay.<xref rid="cit0050" ref-type="bibr"><sup>50</sup></xref> In the presence of RNase, the stability of the aptamer candidate, thioRNA59, had a half-life of 1174 mins and was stable even after 12&#160;h of incubation, which was 50&#160;times greater than that of the corresponding natural RNA (completely degraded in the presence of RNase A in 3&#160;h), and it also showed high binding affinity to thrombin with a K<sub>d</sub> of 4.7&#160;nM.<xref rid="cit0050" ref-type="bibr"><sup>50</sup></xref></p></sec><sec id="s0005-0006"><title>2&#8242;-fluroarabino nucleic acid (2&#8242;-FANA) modified aptamers</title><p>Very recently, <italic>Alves Ferreira-Bravo et&#160;al.</italic> reported a 2&#8242;-FANA aptamer to human immunodeficiency virus-1 (HIV-1) reverse transcriptase.<xref rid="cit0051" ref-type="bibr"><sup>51</sup></xref> This 2&#8242;-FANA aptamer was isolated from a 2&#8242;-FANA modified DNA pool through SELEX using electrophoretic mobility shift assay.<xref rid="cit0051" ref-type="bibr"><sup>51</sup></xref> The developed 2&#8242;-FANA modified DNA aptamer, FA<sub>1</sub> had a K<sub>d</sub> value of 4 pM and showed greater resistance to nucleases.<xref rid="cit0051" ref-type="bibr"><sup>51</sup></xref></p></sec><sec id="s0005-0007"><title>1,5-anhydro hexitol nucleic acid (HNA) modified aptamers</title><p><italic>Pinheiro et&#160;al.</italic> developed HNA aptamers against HIV-1 transactivation responsive element (TAR) and hen egg lysozyme through SELEX using magnetic bead-based separation.<xref rid="cit0052" ref-type="bibr"><sup>52</sup></xref> HNA aptamer, T5-S8-7 bound to TAR with high specificity and had a K<sub>d</sub> of 28&#8211;67&#160;nM.<xref rid="cit0052" ref-type="bibr"><sup>52</sup></xref> HNA aptamers that bound specifically to hen egg lysozyme had a K<sub>d</sub> of 107 to 141&#160;nM as determined by surface plasmon resonance.<xref rid="cit0052" ref-type="bibr"><sup>52</sup></xref></p></sec><sec id="s0005-0008"><title>Threose nucleic acid (TNA) modified aptamers</title><p><italic>Yu et&#160;al.</italic> selected a TNA modified aptamer against thrombin using affinity column and capillary electrophoresis.<xref rid="cit0053" ref-type="bibr"><sup>53,54</sup></xref> TNA backbone is nuclease-resistant as TNA remained undigested even after 72&#160;h of incubation with a pure nuclease unlike DNA and RNA which exhibit half-lives of 30 mins and less than 10s respectively.<xref rid="cit0054" ref-type="bibr"><sup>54</sup></xref> The developed TNA aptamers to thrombin had a K<sub>d</sub> in the range of 200&#8211;900&#160;nM.<xref rid="cit0053" ref-type="bibr"><sup>53</sup></xref> A new manganese-independent TNA polymerase was evolved using droplet-based optical polymerase sorting which can be used in TNA aptamer selection protocol.<xref rid="cit0055" ref-type="bibr"><sup>55</sup></xref></p></sec><sec id="s0005-0009"><title>Locked nucleic acid (LNA) modified aptamers</title><p>In LNA, the sugar ring is locked by a 2&#8242;O, 4&#8242;C methylene linkage and is conformationally restricted adopting a C3&#8242;-endo conformation.<xref rid="cit0056" ref-type="bibr"><sup>56-61</sup></xref> Toward the development of LNA-modified aptamers, <italic>Veedu et&#160;al.</italic> and others have extensively investigated the enzymatic recognition capabilities of LNA-nucleotides.<xref rid="cit0058" ref-type="bibr"><sup>58-68</sup></xref> DNA aptamers containing LNA (BNA/LNA) nucleotides were developed against human thrombin using capillary electrophoresis SELEX. BNA/LNA-modified nucleotides were introduced in the primer-binding region of the library, and after selection the selected candidates were enriched by PCR using the LNA-modified primer sequence to regenerate the selected aptamer candidates using KOD polymerase.<xref rid="cit0023" ref-type="bibr"><sup>23,69</sup></xref> Many aptamers showed K<sub>d</sub> values in the low nanomolar range.<xref rid="cit0023" ref-type="bibr"><sup>23,70</sup></xref> In another study, <italic>Elle et&#160;al.</italic> generated LNA-modified aptamers against CD73 immobilized on anti-His tag plates.<xref rid="cit0022" ref-type="bibr"><sup>22</sup></xref> A LNA-modified DNA aptamer NAC6772 showed high binding affinity to CD73 through surface plasmon resonance experiment with a K<sub>d</sub> of 3.54&#160;nM and inhibited the CD73 activity by 85%.<xref rid="cit0022" ref-type="bibr"><sup>22</sup></xref></p></sec></sec><sec><title/><sec disp-level="2" id="s0005-0010"><title>Spiegelmers</title><p>Spiegelmers are mirror images of the natural aptamers in which the D-ribose (the natural ribose) are replaced with the unnatural L-ribose. Spiegelmers prevent enzymatic degradation as the chiral form of the nucleic acid (the L-form) is unnatural and is not recognized by nucleases. However, the L-form of the nucleic acid like their D-form natural counter parts can bind to the target with high affinity and will not trigger the immune response. Similar to the other sugar modifications described above, spiegelmers can be enriched by T7 RNA polymerases. <italic>Klussmann et&#160;al.</italic> generated one of the first spiegelmers through SELEX against the naturally occurring D-adenosine.<xref rid="cit0071" ref-type="bibr"><sup>71</sup></xref> The high affinity L-RNA aptamers against D-adenosine were isolated through affinity column and had a K<sub>d</sub> of 1.7&#160;&#181;M which was comparable to the affinity displayed by the D-RNA aptamers.<xref rid="cit0071" ref-type="bibr"><sup>71</sup></xref>
<italic>Nolte et&#160;al.</italic> reported another spiegelmer that bound to <sc>L</sc>-arginine that could also bind to a short peptide that contains an arginine-rich region in HIV-1 Tat protein.<xref rid="cit0072" ref-type="bibr"><sup>72</sup></xref> The aptamer, L-R16c was isolated through affinity column based SELEX.<xref rid="cit0072" ref-type="bibr"><sup>72</sup></xref> L-R16c bound to <sc>L</sc>-arginine with a K<sub>d</sub> of 129&#160;&#181;M and to the Tat protein with a K<sub>d</sub> of 26&#160;&#181;M.<xref rid="cit0072" ref-type="bibr"><sup>72</sup></xref> L-R16c was very stable in serum and did not degrade even after 60&#160;h of incubation.<xref rid="cit0072" ref-type="bibr"><sup>72</sup></xref> In another study, spiegelmers were selected against D-vasopressin and D-staphylococcal enterotoxin B through SELEX using electrophoretic mobility shift assay.<xref rid="cit0073" ref-type="bibr"><sup>73</sup></xref> The L-DNA aptamers targeting D-vasopressin showed no degradation with exo- and endonucleases and showed high binding affinity for D-vasopressin with a K<sub>d</sub> of 0.9&#160;&#181;M.<xref rid="cit0073" ref-type="bibr"><sup>73</sup></xref> The corresponding D-aptamer degraded in 10&#160;s while the L-aptamer showed no degradation even after 10 days incubation with exo- and endonucleases and 7 days in serum.<xref rid="cit0073" ref-type="bibr"><sup>73</sup></xref> A DNA spiegelmer targeting D-staphylococcal enterotoxin B, B12b10 had a K<sub>d</sub> of 200&#160;nM.<xref rid="cit0074" ref-type="bibr"><sup>74</sup></xref>
<italic>Vater et&#160;al.</italic> isolated a RNA spiegelmer against migraine associated calcitonin gene-related peptide through SELEX using affinity columns.<xref rid="cit0075" ref-type="bibr"><sup>75</sup></xref> The developed RNA spiegelmer STAR-F12 bound to calcitonin gene-related peptide with a K<sub>d</sub> of 2.5&#160;nM and inhibits its activity.<xref rid="cit0075" ref-type="bibr"><sup>75</sup></xref> In another study, a RNA spiegelmer targeting Substance P was generated through SELEX using affinity column.<xref rid="cit0076" ref-type="bibr"><sup>76</sup></xref> The developed L-RNA aptamer, SUP-A-004, which was further truncated and the resulting spiegelmer bound to Substance P with a K<sub>d</sub> of 40&#160;nM.<xref rid="cit0076" ref-type="bibr"><sup>76</sup></xref> SUP-A-004 inhibited L-substance P mediated Ca<sup>2+</sup> release in AR42J pancreatic cells.<xref rid="cit0076" ref-type="bibr"><sup>76</sup></xref>
<italic>Faulhammer et&#160;al.</italic>, in another study reported the development of L-RNA aptamers NOX2149 and NOX2137 against Nociceptin/orphanin FQ through SELEX using affinity column.<xref rid="cit0077" ref-type="bibr"><sup>77</sup></xref> The L-NOX2149 and L-NOX2137 bound to the nociception/orphanin FQ with a K<sub>d</sub> of 0.3&#160;&#181;M and 0.7&#160;&#181;M respectively which were similar to the binding affinity to their D-aptamer counterparts.<xref rid="cit0077" ref-type="bibr"><sup>77</sup></xref> However L-aptamers had the advantage of being more stable in serum.<xref rid="cit0077" ref-type="bibr"><sup>77</sup></xref> In another study, L-DNA/RNA aptamers that bind to D-gonadotropin-releasing hormone with high affinity and specificity were isolated out of L-RNA and DNA libraries through SELEX using affinity column.<xref rid="cit0078" ref-type="bibr"><sup>78</sup></xref> The L-DNA aptamer, S42 bound to gonadotropin-releasing hormone with a K<sub>d</sub> of 45&#160;nM which is similar to that of the D-DNA aptamer and the IC<sub>50</sub> was 50&#160;nM.<xref rid="cit0078" ref-type="bibr"><sup>78</sup></xref> The D-RNA aptamer, A10 bound with K<sub>d</sub> of 55&#160;nM, however the K<sub>d</sub> of L-RNA aptamer could not be obtained.<xref rid="cit0078" ref-type="bibr"><sup>78</sup></xref> Both the DNA and RNA spiegelmers bound to gonadotropin-releasing hormones and inhibited their binding to their receptor in Chinese hamster ovary cells and there was no immune response produced in zimmermann rabbits.<xref rid="cit0078" ref-type="bibr"><sup>78</sup></xref>
<italic>Helming et&#160;al.</italic> reported L-RNA aptamers targeting ghrelin through SELEX using electrophoretic mobility shift assay.<xref rid="cit0079" ref-type="bibr"><sup>79,80</sup></xref> L-NOX-B11, a L-RNA aptamer was isolated and bound to ghrelin with high affinity with a K<sub>d</sub> of 44.4&#160;nM.<xref rid="cit0080" ref-type="bibr"><sup>80</sup></xref> L-NOX-B11 inhibited ghrelin from binding to its receptor with an IC<sub>50</sub> value of 5&#160;nM in Chinese hamster ovary cells.<xref rid="cit0079" ref-type="bibr"><sup>79,80</sup></xref> NOXXON Pharma have developed many spiegelmers against various targets and a few of the spiegelmers are in various stages of the preclinical and clinical trials, two of which are described in a recent review by <italic>Sundaram et&#160;al.</italic> NOX-A12 is a spiegelmer that bound to and inhibits stroma cell-derived factor-1.<xref rid="cit0081" ref-type="bibr"><sup>81</sup></xref> After completion of Phase I and Phase IIa trials of NOX-A12, Phase 3 trials have been planned for multiple myeloma.<xref rid="cit0081" ref-type="bibr"><sup>81</sup></xref> Also, Phase 2b/3 trials have been planned for the same candidate against glioblastoma.<xref rid="cit0081" ref-type="bibr"><sup>81</sup></xref> Phase 2a clinical trials have been completed for another spiegelmer, NOX-E36, targeting monocyte chemoattractant- protein 1.<xref rid="cit0081" ref-type="bibr"><sup>81</sup></xref> Several other candidates are currently in different stages of clinical investigation.<xref rid="cit0082" ref-type="bibr"><sup>82</sup></xref> NOX-D20 is another spiegelmer that binds to anaphylatoxin C5a with picomolar affinity and is being considered for preclinical and clinical development.<xref rid="cit0083" ref-type="bibr"><sup>83</sup></xref>
<italic>Wang et&#160;al.</italic> has described the generation of a chemically-synthesized D-amino acid polymerase that is capable of recognizing and catalyzing transcription and polymerisation of an L-DNA template.<xref rid="cit0084" ref-type="bibr"><sup>84</sup></xref> This polymerase could result in generation of new speigelmers in the future.<xref rid="cit0084" ref-type="bibr"><sup>84</sup></xref></p></sec></sec><sec id="s0006"><title>Aptamer selection using modified nucleotide bases</title><p>Incorporating chemical modification to the nucleotide bases could increase the stability and target-binding affinity of aptamers. A number of researchers have succeeded in generating aptamers with base-modified nucleotides (<xref ref-type="fig" rid="f0004">Fig.&#160;4</xref>), some of which are in preclinical stages. Various base modifications are incorporated into the nucleic acid library and in many cases have been able to be amplified using family B-DNA polymerases.<xref rid="cit0085" ref-type="bibr"><sup>85</sup></xref>
<xref ref-type="table" rid="t0002">Table&#160;2</xref> provides a summary of base-modified aptamer development. There is also a new method called click-SELEX which is used to generate base-modified libraries by replacing the thymidines with C5-ethynyl-2&#8242;-deoxyuridine which is then further modified through click reaction with copper(I)-catalyzed alkyne-azide cycloaddition.<xref rid="cit0086" ref-type="bibr"><sup>86-91</sup></xref> The library is then used in selection experiments to evolve modified aptamers.<xref rid="cit0086" ref-type="bibr"><sup>86-91</sup></xref> This is a powerful method that allows generation of modified aptamers with new chemical modifications without problems caused by lack of enzymatic recognition as seen with the addition of a cluster of oligomannose glycans.<xref rid="cit0086" ref-type="bibr"><sup>86-91</sup></xref> This will allow targeting of many molecules and epitopes that is currently not possible with standard SELEX.<xref rid="cit0086" ref-type="bibr"><sup>86-91</sup></xref> Addition of new nucleotides and/or unnatural base pairs to the libraries and using these libraries for aptamer selection allows generation of modified aptamers with greater sequence and functional diversity.<xref rid="cit0092" ref-type="bibr"><sup>92-95</sup></xref>
<italic>Zhang et&#160;al.</italic> has shown that addition of new nucleotides Z and P allowed generation of sequences that had better binding affinity to the target molecule indicating that new nucleotides are viable in the library and can show higher binding affinity than natural bases in some cases.<xref rid="cit0092" ref-type="bibr"><sup>92</sup></xref>
<fig id="f0004" orientation="portrait" position="float"><label>Figure 4.</label><caption><p>Structures of various base-modified nucleotides used in aptamer selection by SELEX methodologies.</p></caption><graphic xlink:href="krnb-13-12-1236173-g004"/></fig>
<table-wrap id="t0002" orientation="portrait" position="float"><label>Table 2.</label><caption><p>Aptamers selected from base-modified DNA/RNA libraries and the binding affinity of aptamers to their targets.</p></caption><!--OASIS TABLE HERE--></table-wrap>
</p><sec id="s0006-0001"><title>Uridine modifications</title><p><italic>Latham et&#160;al.</italic> developed a modified aptamer containing 5-(1-pentynyl)-2&#8242;-deoxyuridine against thrombin by affinity column.<xref rid="cit0096" ref-type="bibr"><sup>96</sup></xref> The affinity of the selected aptamer pool was 400&#160;nM.<xref rid="cit0096" ref-type="bibr"><sup>96</sup></xref> This was one of the first examples of using a base-modified nucleic acid library for screening aptamers. In another study, <italic>Jensen et&#160;al.</italic> developed RNA aptamers from a random RNA library containing photoreactive chromophore 5-iodouridine using crosslinking SELEX.<xref rid="cit0097" ref-type="bibr"><sup>97</sup></xref> The selected RNA aptamers bound and also cross-linked to the target with UV irradiation.<xref rid="cit0097" ref-type="bibr"><sup>97</sup></xref> These modified aptamers had high affinity with a K<sub>d</sub> of 0.8&#160;nM.<xref rid="cit0097" ref-type="bibr"><sup>97</sup></xref>
<italic>Battersby et&#160;al.</italic> isolated another base-modified aptamer containing 5-aminopropynyl-deoxyuridine against ATP by electrophoretic mobility shift assay.<xref rid="cit0098" ref-type="bibr"><sup>98,99</sup></xref> One of the selected aptamer candidate, 409 was found to bind ATP with higher affinity (K<sub>d</sub> = 6&#160;&#181;M) than their unmodified counterparts.<xref rid="cit0098" ref-type="bibr"><sup>98,99</sup></xref>
<italic>Shoji et&#160;al.</italic> reported another base-modified aptamer with 5&#8242;-N-6-NH<sub>2</sub>-hexyl carbamoylmethyl dU.<xref rid="cit0100" ref-type="bibr"><sup>100,101</sup></xref> The modified library was used to screen aptamers against thalidomide using streptavidin-sepharose gel.<xref rid="cit0100" ref-type="bibr"><sup>100</sup></xref> Surface plasmon resonance showed that the selected base-modified aptamer T5N and T51B had a K<sub>d</sub> of 113&#160;&#181;M and 133&#160;&#181;M respectively.<xref rid="cit0100" ref-type="bibr"><sup>100</sup></xref>
<italic>Li et&#160;al.</italic> selected an aptamer containing boronic acid-modified thymidine against fibrinogen using magnetic bead immobilization-based SELEX.<xref rid="cit0102" ref-type="bibr"><sup>102</sup></xref> The resulting modified aptamers bound to fibrinogen with high affinity compared to that of the unmodified aptamers (K<sub>d</sub> = 3&#8211;30&#160;nM compared to K<sub>d</sub> = 450&#160;nM).<xref rid="cit0102" ref-type="bibr"><sup>102</sup></xref>
<italic>Vaught et&#160;al.</italic> selected a DNA aptamer against tumor necrosis factor receptor super family 9 from a library possessing 5-amide-modified deoxyuridine via a magnetic bead-based SELEX method.<xref rid="cit0103" ref-type="bibr"><sup>103</sup></xref> Six 5-position modified 2&#8242;-dUTP derivatives were used.<xref rid="cit0103" ref-type="bibr"><sup>103</sup></xref> Two of the modified DNA aptamers developed showed high affinity (K<sub>d</sub> = 6&#160;nM and 4&#160;nM respectively) compared to an unmodified RNA aptamer that has been previously reported (K<sub>d</sub> = 40&#160;nM).<xref rid="cit0103" ref-type="bibr"><sup>103</sup></xref></p></sec><sec id="s0006-0002"><title>Imidazole modifications</title><p>Aptamers can also act as DNA enzymes which are catalytic nucleic acids and modified libraries have been used to select such aptamers. <italic>Sontoro et&#160;al.</italic> developed a modified DNAzyme aptamer via affinity column from a modified library containing C5-imidazole-functionalised dU.<xref rid="cit0104" ref-type="bibr"><sup>104</sup></xref> The isolated DNAzyme was one of the smallest nucleic acid enzymes, which showed multiple turnovers in the presence of millimolar concentrations of Zn<sup>2+</sup>, and a catalytic rate of 1.4&#8211;1.5&#160;min<sup>&#8722;1</sup> for cleavage.<xref rid="cit0104" ref-type="bibr"><sup>104</sup></xref>
<italic>Kimoto et&#160;al.</italic> reported the selection of 7-(2-thienyl)imidazole[4,5-<italic>b</italic>]pyridine modified DNA aptamers against VEGF<sub>165</sub> and IFN-&#947; by magnetic bead-based SELEX.<xref rid="cit0105" ref-type="bibr"><sup>105</sup></xref> The isolated DNA aptamers bound to VEGF<sub>165</sub> and IFN-&#947; with 100 fold higher affinity than their natural counterparts with K<sub>d</sub> values of 0.64 pM and 0.038&#160;nM respectively.<xref rid="cit0105" ref-type="bibr"><sup>105</sup></xref>
<italic>Hollenstein et&#160;al.</italic> reported the development of Dz12&#8211;91, a modified DNAzyme containing imidazole, ammonium and guanidinium groups. Dz12&#8211;91 was isolated through SELEX using magnetic streptavidin particles and cleaves all RNA sequence independently of M<sup>2+</sup> with a K<sub>obs</sub> of 0.06&#160;min<sup>&#8722;1</sup>.<xref rid="cit0106" ref-type="bibr"><sup>106</sup></xref></p></sec><sec id="s0006-0003"><title>Slow off-rate modified aptamers (SOMAmers)</title><p>Another class of aptamers with improved binding properties through base-modifications that result in slow dissociation rates called SOMAmers. There are many SOMAmer modifications that are used to generate aptamers to difficult protein targets.<xref rid="cit0107" ref-type="bibr"><sup>107</sup></xref> The affinities of the SOMAmers are consistently in the nanomolar range to their targets and show high nuclease resistance.<xref rid="cit0107" ref-type="bibr"><sup>107</sup></xref> Various proteins have been used as targets to generate SOMAmers.<xref rid="cit0107" ref-type="bibr"><sup>107,108</sup></xref> In many SOMAmers, the modifications are introduced at the 5-position of the uridine nucleotide.<xref rid="cit0107" ref-type="bibr"><sup>107</sup></xref>
<italic>Gold et&#160;al.</italic> described the development of SOMAmers against more than 800 targets using multiplex SOMAmer affinity assay system from base-modified libraries including 5-benzylaminocarbonyl, 5-naphthylmethylaminocarbonyl, 5-tryptaminocarbonyl, 5-isobutylaminocarbonyl, 5-tyrosyl, 5-phenylethyl, and 5-guanidinoallyl.<xref rid="cit0107" ref-type="bibr"><sup>107,109</sup></xref>
<italic>Ochsner et&#160;al.</italic> reported development of SOMAmers against toxins A, B and binary toxins using 5-benzylaminocarbonyl, 5-naphthylmethylaminocarbonyl, 5-tryptaminocarbonyl, 5-phenylethyl-1-aminocarbonyl, 5-tyrosylaminocarbonyl or 5-(2-naphthylmethyl)aminocarbonyl-modified uridine containing library using magnetic bead-based SELEX.<xref rid="cit0109" ref-type="bibr"><sup>109</sup></xref> Most of the modified aptamers bound to the toxin A and B with high binding affinity with the K<sub>d</sub> in the nanomolar range.<xref rid="cit0109" ref-type="bibr"><sup>109</sup></xref> For example, the selected 5-tryptaminocarbonyl dU modified aptamer showed a K<sub>d</sub> of 1.7&#160;nM to Toxin A and 0.45&#160;nM for Toxin B.<xref rid="cit0109" ref-type="bibr"><sup>109</sup></xref></p></sec></sec><sec id="s0007"><title>Aptamer selection using phosphate modified nucleotides</title><p>A few phosphate-modified aptamers (<xref ref-type="fig" rid="f0005">Fig.&#160;5</xref>) were reported as substrates of T7 RNA polymerase that could accept the triphosphate analogs of the modified phosphate moiety, mainly phosphorothioate and boranophosphates. <xref ref-type="table" rid="t0003">Table&#160;3</xref> provides a summary of base-modified aptamer development.
<fig id="f0005" orientation="portrait" position="float"><label>Figure 5.</label><caption><p>Structures of various phosphate-modified nucleotides used in aptamer selection by SELEX methodologies.</p></caption><graphic xlink:href="krnb-13-12-1236173-g005"/></fig>
<table-wrap id="t0003" orientation="portrait" position="float"><label>Table 3.</label><caption><p>Aptamers selected from phosphate-modified DNA/RNA libraries and the binding affinity of aptamers to their targets.</p></caption><!--OASIS TABLE HERE--></table-wrap>
</p><sec id="s0007-0001"><title>Phosphorothioate modifications</title><p>Through nitrocellulose membrane filter binding, phosphothioate-modifed RNA aptamer 11&#8211;20 was isolated that bound to bFGF with a K<sub>d</sub> of 1.8&#160;nM which was similar to the K<sub>d</sub> of all RNA aptamers (K<sub>d</sub> = 0.19&#160;nM and 0.49&#160;nM).<xref rid="cit0110" ref-type="bibr"><sup>110</sup></xref> K<sub>d</sub> of another bFGF aptamer containing 2&#8242;-NH<sub>2</sub> pyrimidines was 0.35&#160;nM, which was also comparable to the unmodified RNA aptamers.<xref rid="cit0110" ref-type="bibr"><sup>110</sup></xref> These aptamers also bound to other bFGF members in the family, but not to the unrelated targets and were therefore &#8220;semi-specific&#8221; for the FGF family members.<xref rid="cit0110" ref-type="bibr"><sup>110</sup></xref> Another phosphorothioate DNA aptamer was selected against nuclear factor for human interleukin 6 which was nuclease-resistant to DNase 1 enzyme at the point of modifications.<xref rid="cit0111" ref-type="bibr"><sup>111,112</sup></xref> This modified DNA aptamer was selected through nitrocellulose filter binding from a library with thiophosphate backbone substitution at the thymidine positions and the modified aptamer was found to bind with stoichemistry of two protein dimers/duplex unlike the unmodified aptamer which bound with one protein dimer/duplex stoichemistry.<xref rid="cit0112" ref-type="bibr"><sup>112</sup></xref> The binding constant (K<sub>obs</sub>) measured by fluorescence anisotropy was 2&#160;nM for a 66-mer.<xref rid="cit0112" ref-type="bibr"><sup>112</sup></xref> Another phosphorothioate aptamer was selected against Nuclear Factor kappa B proteins Rel A (p65) and p50 and the selected aptamer had a K<sub>d</sub> value of 4.8&#160;nM and 0.8&#160;nM respectively, which was comparable to the unmodified aptamer (K<sub>d</sub> = 4.77&#160;nM).<xref rid="cit0111" ref-type="bibr"><sup>111</sup></xref></p></sec><sec id="s0007-0002"><title>Boranophosphate modification</title><p>Boronated nucleotide analog modifications of guanosine (5&#8242;(&#945;-<italic>P-borano</italic>)triphosphate) for GTP and uridine (5&#8242;(&#945;-<italic>P-borano</italic>)triphosphate) for UTP were also introduced into general libraries to select modified aptamers that bind ATP through affinity matrix containing C8-linked ATP agarose.<xref rid="cit0113" ref-type="bibr"><sup>113</sup></xref> Each of the 2 modifications were tolerated in the backbone alone, however both modifications in one backbone were not tolerated.<xref rid="cit0113" ref-type="bibr"><sup>113</sup></xref></p></sec></sec><sec id="s0008"><title>Conclusions and future perspectives</title><p>Aptamers are nucleic acid ligands that are generally developed through SELEX and bind to their targets with high affinity and specificity. Aptamers can be used therapeutically, diagnostically, as molecular beacons or as DNAzymes in various diseases. Macugen is a therapeutic aptamer approved by the US FDA for the treatment of AMD. One of the major disadvantages of aptamers composed of natural nucleotides is their rapid degradation <italic>in vivo</italic>. To overcome this obstacle, chemically-modified aptamers have been developed through SELEX using modified-oligonucleotide libraries. There are many potential chemically-modified nucleotides with excellent properties, however many of them cannot be used in the SELEX processes to develop aptamers mainly because of their very limited enzymatic recognition capabilities which are required for enrichment steps. As reviewed here, it is very promising to see the development of chemically-modified aptamers using several sugar, base and phosphate-modified nucleotides. It is also very encouraging to note the development of novel engineered polymerases capable of recognizing a specific modified nucleotide. Recent developments in one-step-based selection methodologies further offer tremendous hope for developing aptamers containing modified aptamers with limited enzymatic recognition capabilities.</p></sec></body><back><sec><title>Disclosure of potential conflicts of interest</title><p>No potential conflicts of interest were disclosed.</p></sec><sec><title>Acknowledgment</title><p>RNV acknowledges the funding from McCusker Charitable Foundation, and Western Australian Neuroscience Research Institute. MC thanks the funding from Greg and Dale Higham.</p></sec><ref-list><title>References</title><ref id="cit0001"><label>1.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Keefe</surname><given-names>AD</given-names></name>, <name name-style="western"><surname>Pai</surname><given-names>S</given-names></name>, <name name-style="western"><surname>Ellington</surname><given-names>A</given-names></name></person-group>. <article-title>Aptamers as therapeutics</article-title>. <source>Nat Rev Drug Discov</source>
<year>2010</year>; <volume>9</volume>:<fpage>537</fpage>-<lpage>50</lpage>; PMID:20592747; http://dx.doi.org/<pub-id pub-id-type="doi">10.1038/nrd3141</pub-id><?supplied-pmid 20592747?><pub-id pub-id-type="pmid">20592747</pub-id></mixed-citation></ref><ref id="cit0002"><label>2.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Nimjee</surname><given-names>SM</given-names></name>, <name name-style="western"><surname>Rusconi</surname><given-names>CP</given-names></name>, <name name-style="western"><surname>Sullenger</surname><given-names>BA</given-names></name></person-group>. <article-title>Aptamers: an emerging class of therapeutics</article-title>. <source>Annu Rev Med</source>
<year>2005</year>; <volume>56</volume>:<fpage>555</fpage>-<lpage>83</lpage>; PMID:15660527; http://dx.doi.org/<pub-id pub-id-type="doi">10.1146/annurev.med.56.062904.144915</pub-id><?supplied-pmid 15660527?><pub-id pub-id-type="pmid">15660527</pub-id></mixed-citation></ref><ref id="cit0003"><label>3.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Famulok</surname><given-names>M</given-names></name>, <name name-style="western"><surname>Hartig</surname><given-names>JS</given-names></name>, <name name-style="western"><surname>Mayer</surname><given-names>G</given-names></name></person-group>. <article-title>Functional aptamers and aptazymes in biotechnology, diagnostics, and therapy</article-title>. <source>Chem Rev</source>
<year>2007</year>; <volume>107</volume>:<fpage>3715</fpage>-<lpage>43</lpage>; PMID:17715981; http://dx.doi.org/<pub-id pub-id-type="doi">10.1021/cr0306743</pub-id><?supplied-pmid 17715981?><pub-id pub-id-type="pmid">17715981</pub-id></mixed-citation></ref><ref id="cit0004"><label>4.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Veedu</surname><given-names>RN</given-names></name></person-group>. <article-title>Editorial (Thematic Issue: Medicinal Chemistry of Aptamers)</article-title>. <source>Curr Top Med Chem</source>
<year>2015</year>; <volume>15</volume>:<fpage>1065</fpage>; PMID:25866280; http://dx.doi.org/<pub-id pub-id-type="doi">10.2174/1568026615666150413161707</pub-id><?supplied-pmid 25866280?><pub-id pub-id-type="pmid">25866280</pub-id></mixed-citation></ref><ref id="cit0005"><label>5.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Jayasena</surname><given-names>SD</given-names></name></person-group>. <article-title>Aptamers: an emerging class of molecules that rival antibodies in diagnostics</article-title>. <source>Clin Chem</source>
<year>1999</year>; <volume>45</volume>:<fpage>1628</fpage>-<lpage>50</lpage>; PMID:10471678<?supplied-pmid 10471678?><pub-id pub-id-type="pmid">10471678</pub-id></mixed-citation></ref><ref id="cit0006"><label>6.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Stoltenburg</surname><given-names>R</given-names></name>, <name name-style="western"><surname>Reinemann</surname><given-names>C</given-names></name>, <name name-style="western"><surname>Strehlitz</surname><given-names>B</given-names></name></person-group>. <article-title>SELEX&#8212;a (r) evolutionary method to generate high-affinity nucleic acid ligands</article-title>. <source>Biomol Eng</source>
<year>2007</year>; <volume>24</volume>:<fpage>381</fpage>-<lpage>403</lpage>; PMID:17627883; http://dx.doi.org/<pub-id pub-id-type="doi">10.1016/j.bioeng.2007.06.001</pub-id><?supplied-pmid 17627883?><pub-id pub-id-type="pmid">17627883</pub-id></mixed-citation></ref><ref id="cit0007"><label>7.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Gopinath</surname><given-names>SCB</given-names></name></person-group>. <article-title>Methods developed for SELEX</article-title>. <source>Anal Bioanal Chem</source>
<year>2007</year>; <volume>387</volume>:<fpage>171</fpage>-<lpage>82</lpage>; PMID:17072603; http://dx.doi.org/<pub-id pub-id-type="doi">10.1007/s00216-006-0826-2</pub-id><?supplied-pmid 17072603?><pub-id pub-id-type="pmid">17072603</pub-id></mixed-citation></ref><ref id="cit0008"><label>8.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Demarest</surname><given-names>SJ</given-names></name>, <name name-style="western"><surname>Glaser</surname><given-names>SM</given-names></name></person-group>. <article-title>Antibody therapeutics, antibody engineering, and the merits of protein stability</article-title>. <source>Curr Opin Drug Discov Devel</source>
<year>2008</year>; <volume>11</volume>:<fpage>675</fpage>-<lpage>87</lpage>; PMID:18729019<?supplied-pmid 18729019?><pub-id pub-id-type="pmid">18729019</pub-id></mixed-citation></ref><ref id="cit0009"><label>9.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Ng</surname><given-names>EWM</given-names></name>, <name name-style="western"><surname>Shima</surname><given-names>DT</given-names></name>, <name name-style="western"><surname>Calias</surname><given-names>P</given-names></name>, <name name-style="western"><surname>Cunningham</surname><given-names>ET</given-names></name>, <name name-style="western"><surname>Guyer</surname><given-names>DR</given-names></name>, <name name-style="western"><surname>Adamis</surname><given-names>AP</given-names></name></person-group>. <article-title>Pegaptanib, a targeted anti-VEGF aptamer for ocular vascular disease</article-title>. <source>Nat Rev Drug Discov</source>
<year>2006</year>; <volume>5</volume>:<fpage>123</fpage>-<lpage>32</lpage>; PMID:16518379; http://dx.doi.org/<pub-id pub-id-type="doi">10.1038/nrd1955</pub-id><?supplied-pmid 16518379?><pub-id pub-id-type="pmid">16518379</pub-id></mixed-citation></ref><ref id="cit0010"><label>10.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Group</surname><given-names>MDRS</given-names></name></person-group>. <article-title>A phase II randomized double-masked trial of pegaptanib, an anti&#8211;vascular endothelial growth factor aptamer, for diabetic macular edema</article-title>. <source>Ophthalmology</source>
<year>2005</year>; <volume>112</volume>:<fpage>1747</fpage>-<lpage>57</lpage>; PMID:16154196; http://dx.doi.org/<pub-id pub-id-type="doi">10.1016/j.ophtha.2005.06.007</pub-id><?supplied-pmid 16154196?><pub-id pub-id-type="pmid">16154196</pub-id></mixed-citation></ref><ref id="cit0011"><label>11.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Kanwar</surname><given-names>JR</given-names></name>, <name name-style="western"><surname>Roy</surname><given-names>K</given-names></name>, <name name-style="western"><surname>Maremanda</surname><given-names>NG</given-names></name>, <name name-style="western"><surname>Subramanian</surname><given-names>K</given-names></name>, <name name-style="western"><surname>Veedu</surname><given-names>RN</given-names></name>, <name name-style="western"><surname>Bawa</surname><given-names>R</given-names></name>, <name name-style="western"><surname>Kanwar</surname><given-names>RK</given-names></name></person-group>. <article-title>Nucleic acid-based aptamers: applications, development and clinical trials</article-title>. <source>Curr Med Chem</source>
<year>2015</year>; <volume>22</volume>:<fpage>2539</fpage>-<lpage>57</lpage>; PMID:25723512; http://dx.doi.org/<pub-id pub-id-type="doi">10.2174/0929867322666150227144909</pub-id><?supplied-pmid 25723512?><pub-id pub-id-type="pmid">25723512</pub-id></mixed-citation></ref><ref id="cit0012"><label>12.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Zuker</surname><given-names>M</given-names></name></person-group>. <article-title>Mfold web server for nucleic acid folding and hybridization prediction</article-title>. <source>Nucleic Acids Res</source>
<year>2003</year>; <volume>31</volume>:<fpage>3406</fpage>-<lpage>15</lpage>; PMID:12824337; http://dx.doi.org/<pub-id pub-id-type="doi">10.1093/nar/gkg595</pub-id><?supplied-pmid 12824337?><pub-id pub-id-type="pmid">12824337</pub-id></mixed-citation></ref><ref id="cit0013"><label>13.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Hofacker</surname><given-names>IL</given-names></name></person-group>. <article-title>Vienna RNA secondary structure server</article-title>. <source>Nucleic Acids Res</source>
<year>2003</year>; <volume>31</volume>:<fpage>3429</fpage>-<lpage>31</lpage>; PMID:12824340; http://dx.doi.org/<pub-id pub-id-type="doi">10.1093/nar/gkg599</pub-id><?supplied-pmid 12824340?><pub-id pub-id-type="pmid">12824340</pub-id></mixed-citation></ref><ref id="cit0014"><label>14.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Diafa</surname><given-names>S</given-names></name>, <name name-style="western"><surname>Hollenstein</surname><given-names>M</given-names></name></person-group>. <article-title>Generation of aptamers with an expanded chemical repertoire</article-title>. <source>Molecules</source>
<year>2015</year>; <volume>20</volume>:<fpage>16643</fpage>-<lpage>71</lpage>; PMID:26389865; http://dx.doi.org/<pub-id pub-id-type="doi">10.3390/molecules200916643</pub-id><?supplied-pmid 26389865?><pub-id pub-id-type="pmid">26389865</pub-id></mixed-citation></ref><ref id="cit0015"><label>15.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Dellafiore</surname><given-names>MA</given-names></name>, <name name-style="western"><surname>Montserrat</surname><given-names>JM</given-names></name>, <name name-style="western"><surname>Iribarren</surname><given-names>AM</given-names></name></person-group>. <article-title>Modified Nucleoside Triphosphates for In-vitro Selection Techniques</article-title>. <source>Front Chem</source>
<year>2016</year>; <volume>4</volume>:<fpage>18</fpage>; PMID:27200340; http://dx.doi.org/<pub-id pub-id-type="doi">10.3389/fchem.2016.00018</pub-id><?supplied-pmid 27200340?><pub-id pub-id-type="pmid">27200340</pub-id></mixed-citation></ref><ref id="cit0016"><label>16.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Kong</surname><given-names>D</given-names></name>, <name name-style="western"><surname>Yeung</surname><given-names>W</given-names></name>, <name name-style="western"><surname>Hili</surname><given-names>R</given-names></name></person-group>. <article-title>Generation of Synthetic Copolymer Libraries by Combinatorial Assembly on Nucleic Acid Templates</article-title>. <source>ACS Comb Sci</source>
<year>2016</year>; <volume>18</volume>:<fpage>355</fpage>-<lpage>70</lpage>; PMID:27275512; http://dx.doi.org/<pub-id pub-id-type="doi">10.1021/acscombsci.6b00059</pub-id><?supplied-pmid 27275512?><pub-id pub-id-type="pmid">27275512</pub-id></mixed-citation></ref><ref id="cit0017"><label>17.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Lapa</surname><given-names>SA</given-names></name>, <name name-style="western"><surname>Chudinov</surname><given-names>AV</given-names></name>, <name name-style="western"><surname>Timofeev</surname><given-names>EN</given-names></name></person-group>. <article-title>The toolbox for modified aptamers</article-title>. <source>Mol Biotechnol</source>
<year>2016</year>; <volume>58</volume>:<fpage>79</fpage>-<lpage>92</lpage>; PMID:26607475; http://dx.doi.org/<pub-id pub-id-type="doi">10.1007/s12033-015-9907-9</pub-id><?supplied-pmid 26607475?><pub-id pub-id-type="pmid">26607475</pub-id></mixed-citation></ref><ref id="cit0018"><label>18.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Rohloff</surname><given-names>JC</given-names></name>, <name name-style="western"><surname>Gelinas</surname><given-names>AD</given-names></name>, <name name-style="western"><surname>Jarvis</surname><given-names>TC</given-names></name>, <name name-style="western"><surname>Ochsner</surname><given-names>UA</given-names></name>, <name name-style="western"><surname>Schneider</surname><given-names>DJ</given-names></name>, <name name-style="western"><surname>Gold</surname><given-names>L</given-names></name>, <name name-style="western"><surname>Janjic</surname><given-names>N</given-names></name></person-group>. <article-title>Nucleic acid ligands with protein-like side chains: modified aptamers and their use as diagnostic and therapeutic agents</article-title>. <source>Mol Ther Nucleic Acids</source>
<year>2014</year>; <volume>3</volume>:<fpage>e201</fpage>; PMID:25291143; http://dx.doi.org/<pub-id pub-id-type="doi">10.1038/mtna.2014.49</pub-id><?supplied-pmid 25291143?><pub-id pub-id-type="pmid">25291143</pub-id></mixed-citation></ref><ref id="cit0019"><label>19.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Lauridsen</surname><given-names>LH</given-names></name>, <name name-style="western"><surname>Rothnagel</surname><given-names>JA</given-names></name>, <name name-style="western"><surname>Veedu</surname><given-names>RN</given-names></name></person-group>. <article-title>Enzymatic recognition of 2&#8242;&#8208;modified ribonucleoside 5&#8242;&#8208;triphosphates: Towards the evolution of versatile aptamers</article-title>. <source>ChemBioChem</source>
<year>2012</year>; <volume>13</volume>:<fpage>19</fpage>-<lpage>25</lpage>; PMID:22162282; http://dx.doi.org/<pub-id pub-id-type="doi">10.1002/cbic.201100648</pub-id><?supplied-pmid 22162282?><pub-id pub-id-type="pmid">22162282</pub-id></mixed-citation></ref><ref id="cit0020"><label>20.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Loakes</surname><given-names>D</given-names></name>, <name name-style="western"><surname>Holliger</surname><given-names>P</given-names></name></person-group>
<article-title>Polymerase engineering: towards the encoded synthesis of unnatural biopolymers</article-title>. <source>Chem Commun</source>
<year>2009</year>:<fpage>4619</fpage>-<lpage>31</lpage>; PMID:19641798; http://dx.doi.org/27016740<pub-id pub-id-type="doi">10.1039/b903307f</pub-id></mixed-citation></ref><ref id="cit0021"><label>21.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Aschenbrenner</surname><given-names>J</given-names></name>, <name name-style="western"><surname>Marx</surname><given-names>A</given-names></name></person-group>. <article-title>Direct and site-specific quantification of RNA 2&#8242;-O-methylation by PCR with an engineered DNA polymerase</article-title>. <source>Nucleic Acids Res</source>
<year>2016</year>; <volume>44</volume>:<fpage>3495</fpage>-<lpage>502</lpage>; PMID:27016740; http://dx.doi.org/<pub-id pub-id-type="doi">10.1093/nar/gkw200</pub-id><?supplied-pmid 27016740?><pub-id pub-id-type="pmid">27016740</pub-id></mixed-citation></ref><ref id="cit0022"><label>22.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Elle</surname><given-names>IC</given-names></name>, <name name-style="western"><surname>Karlsen</surname><given-names>KK</given-names></name>, <name name-style="western"><surname>Terp</surname><given-names>MG</given-names></name>, <name name-style="western"><surname>Larsen</surname><given-names>N</given-names></name>, <name name-style="western"><surname>Nielsen</surname><given-names>R</given-names></name>, <name name-style="western"><surname>Derbyshire</surname><given-names>N</given-names></name>, <name name-style="western"><surname>Mandrup</surname><given-names>S</given-names></name>, <name name-style="western"><surname>Ditzel</surname><given-names>HJ</given-names></name>, <name name-style="western"><surname>Wengel</surname><given-names>J</given-names></name></person-group>. <article-title>Selection of LNA-containing DNA aptamers against recombinant human CD73</article-title>. <source>Mol Biosyst</source>
<year>2015</year>; <volume>11</volume>:<fpage>1260</fpage>-<lpage>70</lpage>; PMID:25720604; http://dx.doi.org/<pub-id pub-id-type="doi">10.1039/C5MB00045A</pub-id><?supplied-pmid 25720604?><pub-id pub-id-type="pmid">25720604</pub-id></mixed-citation></ref><ref id="cit0023"><label>23.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Kasahara</surname><given-names>Y</given-names></name>, <name name-style="western"><surname>Irisawa</surname><given-names>Y</given-names></name>, <name name-style="western"><surname>Ozaki</surname><given-names>H</given-names></name>, <name name-style="western"><surname>Obika</surname><given-names>S</given-names></name>, <name name-style="western"><surname>Kuwahara</surname><given-names>M</given-names></name></person-group>. <article-title>2&#8242;, 4&#8242;-BNA/LNA aptamers: CE-SELEX using a DNA-based library of full-length 2&#8242;-O, 4&#8242;-C-methylene-bridged/linked bicyclic ribonucleotides</article-title>. <source>Bioorg Med Chem Lett</source>
<year>2013</year>; <volume>23</volume>:<fpage>1288</fpage>-<lpage>92</lpage>; PMID:23374873; http://dx.doi.org/<pub-id pub-id-type="doi">10.1016/j.bmcl.2012.12.093</pub-id><?supplied-pmid 23374873?><pub-id pub-id-type="pmid">23374873</pub-id></mixed-citation></ref><ref id="cit0024"><label>24.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Lauridsen</surname><given-names>LH</given-names></name>, <name name-style="western"><surname>Shamaileh</surname><given-names>HA</given-names></name>, <name name-style="western"><surname>Edwards</surname><given-names>SL</given-names></name>, <name name-style="western"><surname>Taran</surname><given-names>E</given-names></name>, <name name-style="western"><surname>Veedu</surname><given-names>RN</given-names></name></person-group>. <article-title>Rapid one-step selection method for generating nucleic acid aptamers: Development of a DNA aptamer against &#945;-bungarotoxin</article-title>. <source>PLoS One</source>
<year>2012</year>; <volume>7</volume>:<fpage>e41702</fpage>; PMID:22860007; http://dx.doi.org/<pub-id pub-id-type="doi">10.1371/journal.pone.0041702</pub-id><?supplied-pmid 22860007?><pub-id pub-id-type="pmid">22860007</pub-id></mixed-citation></ref><ref id="cit0025"><label>25.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Nitsche</surname><given-names>A</given-names></name>, <name name-style="western"><surname>Kurth</surname><given-names>A</given-names></name>, <name name-style="western"><surname>Dunkhorst</surname><given-names>A</given-names></name>, <name name-style="western"><surname>P&#228;nke</surname><given-names>O</given-names></name>, <name name-style="western"><surname>Sielaff</surname><given-names>H</given-names></name>, <name name-style="western"><surname>Junge</surname><given-names>W</given-names></name>, <name name-style="western"><surname>Muth</surname><given-names>D</given-names></name>, <name name-style="western"><surname>Scheller</surname><given-names>F</given-names></name>, <name name-style="western"><surname>St&#246;cklein</surname><given-names>W</given-names></name>, <name name-style="western"><surname>Dahmen</surname><given-names>C</given-names></name></person-group> et al. <article-title>One-step selection of Vaccinia virus-binding DNA aptamers by MonoLEX</article-title>. <source>BMC Biotechnol</source>
<year>2007</year>; 7(1):48; PMID:17199888; http://dx.doi.org/<pub-id pub-id-type="doi">10.1186/1472-6750-7-48</pub-id><?supplied-pmid 17199888?><pub-id pub-id-type="pmid">17199888</pub-id></mixed-citation></ref><ref id="cit0026"><label>26.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Peng</surname><given-names>L</given-names></name>, <name name-style="western"><surname>Stephens</surname><given-names>BJ</given-names></name>, <name name-style="western"><surname>Bonin</surname><given-names>K</given-names></name>, <name name-style="western"><surname>Cubicciotti</surname><given-names>R</given-names></name>, <name name-style="western"><surname>Guthold</surname><given-names>M</given-names></name></person-group>. <article-title>A combined atomic force/fluorescence microscopy technique to select aptamers in a single cycle from a small pool of random oligonucleotides</article-title>. <source>Microsc Res Tech</source>
<year>2007</year>; <volume>70</volume>:<fpage>372</fpage>-<lpage>81</lpage>; PMID:17262788; http://dx.doi.org/<pub-id pub-id-type="doi">10.1002/jemt.20421</pub-id><?supplied-pmid 17262788?><pub-id pub-id-type="pmid">17262788</pub-id></mixed-citation></ref><ref id="cit0027"><label>27.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Fan</surname><given-names>M</given-names></name>, <name name-style="western"><surname>McBurnett</surname><given-names>SR</given-names></name>, <name name-style="western"><surname>Andrews</surname><given-names>CJ</given-names></name>, <name name-style="western"><surname>Allman</surname><given-names>AM</given-names></name>, <name name-style="western"><surname>Bruno</surname><given-names>JG</given-names></name>, <name name-style="western"><surname>Kiel</surname><given-names>JL</given-names></name></person-group>. <article-title>Aptamer selection express: a novel method for rapid single-step selection and sensing of aptamers</article-title>. <source>J Biomol Tech</source>
<year>2008</year>; <volume>19</volume>:<fpage>311</fpage>; PMID:19183794<?supplied-pmid 19183794?><pub-id pub-id-type="pmid">19183794</pub-id></mixed-citation></ref><ref id="cit0028"><label>28.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Lin</surname><given-names>Y</given-names></name>, <name name-style="western"><surname>Qiu</surname><given-names>Q</given-names></name>, <name name-style="western"><surname>Gill</surname><given-names>SC</given-names></name>, <name name-style="western"><surname>Jayasena</surname><given-names>SD</given-names></name></person-group>. <article-title>Modified RNA sequence pools for in vitro selection</article-title>. <source>Nucleic Acids Res</source>
<year>1994</year>; <volume>22</volume>:<fpage>5229</fpage>-<lpage>34</lpage>; PMID:7529404; http://dx.doi.org/<pub-id pub-id-type="doi">10.1093/nar/22.24.5229</pub-id><?supplied-pmid 7529404?><pub-id pub-id-type="pmid">7529404</pub-id></mixed-citation></ref><ref id="cit0029"><label>29.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Green</surname><given-names>LS</given-names></name>, <name name-style="western"><surname>Jellinek</surname><given-names>D</given-names></name>, <name name-style="western"><surname>Bell</surname><given-names>C</given-names></name>, <name name-style="western"><surname>Beebe</surname><given-names>LA</given-names></name>, <name name-style="western"><surname>Feistner</surname><given-names>BD</given-names></name>, <name name-style="western"><surname>Gill</surname><given-names>SC</given-names></name>, <name name-style="western"><surname>Jucker</surname><given-names>FM</given-names></name>, <name name-style="western"><surname>Janji&#263;</surname><given-names>N</given-names></name></person-group>. <article-title>Nuclease-resistant nucleic acid ligands to vascular permeability factor/vascular endothelial growth factor</article-title>. <source>Chem Biol</source>
<year>1995</year>; <volume>2</volume>:<fpage>683</fpage>-<lpage>95</lpage>; PMID:9383475; http://dx.doi.org/<pub-id pub-id-type="doi">10.1016/1074-5521(95)90032-2</pub-id><?supplied-pmid 9383475?><pub-id pub-id-type="pmid">9383475</pub-id></mixed-citation></ref><ref id="cit0030"><label>30.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Beaudry</surname><given-names>A</given-names></name>, <name name-style="western"><surname>DeFoe</surname><given-names>J</given-names></name>, <name name-style="western"><surname>Zinnen</surname><given-names>S</given-names></name>, <name name-style="western"><surname>Burgin</surname><given-names>A</given-names></name>, <name name-style="western"><surname>Beigelman</surname><given-names>L</given-names></name></person-group>. <article-title>In vitro selection of a novel nuclease-resistant RNA phosphodiesterase</article-title>. <source>Chem Biol</source>
<year>2000</year>; <volume>7</volume>:<fpage>323</fpage>-<lpage>34</lpage>; PMID:10801472; http://dx.doi.org/<pub-id pub-id-type="doi">10.1016/S1074-5521(00)00110-1</pub-id><?supplied-pmid 10801472?><pub-id pub-id-type="pmid">10801472</pub-id></mixed-citation></ref><ref id="cit0031"><label>31.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Jellinek</surname><given-names>D</given-names></name>, <name name-style="western"><surname>Green</surname><given-names>LS</given-names></name>, <name name-style="western"><surname>Bell</surname><given-names>C</given-names></name>, <name name-style="western"><surname>Lynott</surname><given-names>CK</given-names></name>, <name name-style="western"><surname>Gill</surname><given-names>N</given-names></name>, <name name-style="western"><surname>Vargeese</surname><given-names>C</given-names></name>, <name name-style="western"><surname>Kirschenheuter</surname><given-names>G</given-names></name>, <name name-style="western"><surname>McGee</surname><given-names>DP</given-names></name>, <name name-style="western"><surname>Abesinghe</surname><given-names>P</given-names></name></person-group>. <article-title>Potent 2&#8242;-amino-2&#8242;-deoxypyrimidine RNA inhibitors of basic fibroblast growth factor</article-title>. <source>Biochemistry</source>
<year>1995</year>; <volume>34</volume>:<fpage>11363</fpage>-<lpage>72</lpage>; PMID:7547864; http://dx.doi.org/<pub-id pub-id-type="doi">10.1021/bi00036a009</pub-id><?supplied-pmid 7547864?><pub-id pub-id-type="pmid">7547864</pub-id></mixed-citation></ref><ref id="cit0032"><label>32.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Bugaut</surname><given-names>A</given-names></name>, <name name-style="western"><surname>Toulm&#233;</surname><given-names>J-J</given-names></name>, <name name-style="western"><surname>Rayner</surname><given-names>B</given-names></name></person-group>. <article-title>SELEX and dynamic combinatorial chemistry interplay for the selection of conjugated RNA aptamers</article-title>. <source>Org Biomol Chem</source>
<year>2006</year>; <volume>4</volume>:<fpage>4082</fpage>-<lpage>8</lpage>; PMID:17312962; http://dx.doi.org/<pub-id pub-id-type="doi">10.1039/b610890c</pub-id><?supplied-pmid 17312962?><pub-id pub-id-type="pmid">17312962</pub-id></mixed-citation></ref><ref id="cit0033"><label>33.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Ruckman</surname><given-names>J</given-names></name>, <name name-style="western"><surname>Green</surname><given-names>LS</given-names></name>, <name name-style="western"><surname>Beeson</surname><given-names>J</given-names></name>, <name name-style="western"><surname>Waugh</surname><given-names>S</given-names></name>, <name name-style="western"><surname>Gillette</surname><given-names>WL</given-names></name>, <name name-style="western"><surname>Henninger</surname><given-names>DD</given-names></name>, <name name-style="western"><surname>Claesson-Welsh</surname><given-names>L</given-names></name>, <name name-style="western"><surname>Janjic</surname><given-names>N</given-names></name></person-group>. <article-title>2&#8242;-Fluoropyrimidine RNA-based aptamers to the 165-amino acid form of vascular endothelial growth factor (VEGF165). Inhibition of receptor binding and VEGF-induced vascular permeability through interactions requiring the exon 7-encoded domain</article-title>. <source>J Biol Chem</source>
<year>1998</year>; <volume>273</volume>:<fpage>20556</fpage>-<lpage>67</lpage>; PMID:9685413; http://dx.doi.org/<pub-id pub-id-type="doi">10.1074/jbc.273.32.20556</pub-id><?supplied-pmid 9685413?><pub-id pub-id-type="pmid">9685413</pub-id></mixed-citation></ref><ref id="cit0034"><label>34.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Lupold</surname><given-names>SE</given-names></name>, <name name-style="western"><surname>Hicke</surname><given-names>BJ</given-names></name>, <name name-style="western"><surname>Lin</surname><given-names>Y</given-names></name>, <name name-style="western"><surname>Coffey</surname><given-names>DS</given-names></name></person-group>. <article-title>Identification and characterization of nuclease-stabilized RNA molecules that bind human prostate cancer cells via the prostate-specific membrane antigen</article-title>. <source>Cancer Res</source>
<year>2002</year>; <volume>62</volume>:<fpage>4029</fpage>-<lpage>33</lpage>; PMID:12124337; http://dx.doi.org/<pub-id pub-id-type="doi">10.1158/0008-5472.can-12-2152</pub-id><?supplied-pmid 12124337?><pub-id pub-id-type="pmid">12124337</pub-id></mixed-citation></ref><ref id="cit0035"><label>35.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>McNamara</surname><given-names>JO</given-names></name>, <name name-style="western"><surname>Andrechek</surname><given-names>ER</given-names></name>, <name name-style="western"><surname>Wang</surname><given-names>Y</given-names></name>, <name name-style="western"><surname>Viles</surname><given-names>KD</given-names></name>, <name name-style="western"><surname>Rempel</surname><given-names>RE</given-names></name>, <name name-style="western"><surname>Gilboa</surname><given-names>E</given-names></name>, <name name-style="western"><surname>Sullenger</surname><given-names>BA</given-names></name>, <name name-style="western"><surname>Giangrande</surname><given-names>PH</given-names></name></person-group>. <article-title>Cell type&#8211;specific delivery of siRNAs with aptamer-siRNA chimeras</article-title>. <source>Nat Biotechnol</source>
<year>2006</year>; <volume>24</volume>:<fpage>1005</fpage>-<lpage>15</lpage>; PMID:16823371; http://dx.doi.org/<pub-id pub-id-type="doi">10.1038/nbt1223</pub-id><?supplied-pmid 16823371?><pub-id pub-id-type="pmid">16823371</pub-id></mixed-citation></ref><ref id="cit0036"><label>36.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Biesecker</surname><given-names>G</given-names></name>, <name name-style="western"><surname>Dihel</surname><given-names>L</given-names></name>, <name name-style="western"><surname>Enney</surname><given-names>K</given-names></name>, <name name-style="western"><surname>Bendele</surname><given-names>RA</given-names></name></person-group>. <article-title>Derivation of RNA aptamer inhibitors of human complement C5</article-title>. <source>Immunopharmacology</source>
<year>1999</year>; <volume>42</volume>:<fpage>219</fpage>-<lpage>30</lpage>; PMID:10408383; http://dx.doi.org/<pub-id pub-id-type="doi">10.1016/S0162-3109(99)00020-X</pub-id><?supplied-pmid 10408383?><pub-id pub-id-type="pmid">10408383</pub-id></mixed-citation></ref><ref id="cit0037"><label>37.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Layzer</surname><given-names>JM</given-names></name>, <name name-style="western"><surname>Sullenger</surname><given-names>BA</given-names></name></person-group>. <article-title>Simultaneous generation of aptamers to multiple gamma-carboxyglutamic acid proteins from a focused aptamer library using DeSELEX and convergent selection</article-title>. <source>Oligonucleotides</source>
<year>2007</year>; <volume>17</volume>:<fpage>1</fpage>-<lpage>11</lpage>; PMID:17461758; http://dx.doi.org/<pub-id pub-id-type="doi">10.1089/oli.2006.0059</pub-id><?supplied-pmid 17461758?><pub-id pub-id-type="pmid">17461758</pub-id></mixed-citation></ref><ref id="cit0038"><label>38.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Rusconi</surname><given-names>CP</given-names></name>, <name name-style="western"><surname>Scardino</surname><given-names>E</given-names></name>, <name name-style="western"><surname>Layzer</surname><given-names>J</given-names></name>, <name name-style="western"><surname>Pitoc</surname><given-names>GA</given-names></name>, <name name-style="western"><surname>Ortel</surname><given-names>TL</given-names></name>, <name name-style="western"><surname>Monroe</surname><given-names>D</given-names></name>, <name name-style="western"><surname>Sullenger</surname><given-names>BA</given-names></name></person-group>. <article-title>RNA aptamers as reversible antagonists of coagulation factor IXa</article-title>. <source>Nature</source>
<year>2002</year>; <volume>419</volume>:<fpage>90</fpage>-<lpage>4</lpage>; PMID:12214238; http://dx.doi.org/<pub-id pub-id-type="doi">10.1038/nature00963</pub-id><?supplied-pmid 12214238?><pub-id pub-id-type="pmid">12214238</pub-id></mixed-citation></ref><ref id="cit0039"><label>39.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Lamberti</surname><given-names>I</given-names></name>, <name name-style="western"><surname>Scarano</surname><given-names>S</given-names></name>, <name name-style="western"><surname>Esposito</surname><given-names>CL</given-names></name>, <name name-style="western"><surname>Antoccia</surname><given-names>A</given-names></name>, <name name-style="western"><surname>Antonini</surname><given-names>G</given-names></name>, <name name-style="western"><surname>Tanzarella</surname><given-names>C</given-names></name>, <name name-style="western"><surname>De Franciscis</surname><given-names>V</given-names></name>, <name name-style="western"><surname>Minunni</surname><given-names>M</given-names></name></person-group>. <article-title>In vitro selection of RNA aptamers against CA125 tumor marker in ovarian cancer and its study by optical biosensing</article-title>. <source>Methods</source>
<year>2016</year>; <volume>97</volume>:<fpage>58</fpage>-<lpage>68</lpage>; PMID:26542762; http://dx.doi.org/<pub-id pub-id-type="doi">10.1016/j.ymeth.2015.10.022</pub-id><?supplied-pmid 26542762?><pub-id pub-id-type="pmid">26542762</pub-id></mixed-citation></ref><ref id="cit0040"><label>40.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Kubik</surname><given-names>MF</given-names></name>, <name name-style="western"><surname>Bell</surname><given-names>C</given-names></name>, <name name-style="western"><surname>Fitzwater</surname><given-names>T</given-names></name>, <name name-style="western"><surname>Watson</surname><given-names>SR</given-names></name>, <name name-style="western"><surname>Tasset</surname><given-names>DM</given-names></name></person-group>. <article-title>Isolation and characterization of 2&#8242;-fluoro-, 2&#8242;-amino-, and 2&#8242;-fluoro-/amino-modified RNA ligands to human IFN-gamma that inhibit receptor binding</article-title>. <source>J Immunol</source>
<year>1997</year>; <volume>159</volume>:<fpage>259</fpage>-<lpage>67</lpage>; PMID:9200462<?supplied-pmid 9200462?><pub-id pub-id-type="pmid">9200462</pub-id></mixed-citation></ref><ref id="cit0041"><label>41.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Pagratis</surname><given-names>NC</given-names></name>, <name name-style="western"><surname>Bell</surname><given-names>C</given-names></name>, <name name-style="western"><surname>Chang</surname><given-names>Y-F</given-names></name>, <name name-style="western"><surname>Jennings</surname><given-names>S</given-names></name>, <name name-style="western"><surname>Fitzwater</surname><given-names>T</given-names></name>, <name name-style="western"><surname>Jellinek</surname><given-names>D</given-names></name>, <name name-style="western"><surname>Dang</surname><given-names>C</given-names></name></person-group>. <article-title>Potent 2&#8242;-amino-, and 2&#8242;-fluoro-2&#8242;-deoxyribonucleotide RNA inhibitors of keratinocyte growth factor</article-title>. <source>Nat Biotechnol</source>
<year>1997</year>; <volume>15</volume>:<fpage>68</fpage>-<lpage>73</lpage>; PMID:9035109; http://dx.doi.org/<pub-id pub-id-type="doi">10.1038/nbt0197-68</pub-id><?supplied-pmid 9035109?><pub-id pub-id-type="pmid">9035109</pub-id></mixed-citation></ref><ref id="cit0042"><label>42.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Burmeister</surname><given-names>PE</given-names></name>, <name name-style="western"><surname>Lewis</surname><given-names>SD</given-names></name>, <name name-style="western"><surname>Silva</surname><given-names>RF</given-names></name>, <name name-style="western"><surname>Preiss</surname><given-names>JR</given-names></name>, <name name-style="western"><surname>Horwitz</surname><given-names>LR</given-names></name>, <name name-style="western"><surname>Pendergrast</surname><given-names>PS</given-names></name>, <name name-style="western"><surname>McCauley</surname><given-names>TG</given-names></name>, <name name-style="western"><surname>Kurz</surname><given-names>JC</given-names></name>, <name name-style="western"><surname>Epstein</surname><given-names>DM</given-names></name>, <name name-style="western"><surname>Wilson</surname><given-names>C</given-names></name></person-group>. <article-title>Direct in vitro selection of a 2&#8242;-O-methyl aptamer to VEGF</article-title>. <source>Chem Biol</source>
<year>2005</year>; <volume>12</volume>:<fpage>25</fpage>-<lpage>33</lpage>; PMID:15664512; http://dx.doi.org/<pub-id pub-id-type="doi">10.1016/j.chembiol.2004.10.017</pub-id><?supplied-pmid 15664512?><pub-id pub-id-type="pmid">15664512</pub-id></mixed-citation></ref><ref id="cit0043"><label>43.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Burmeister</surname><given-names>PE</given-names></name>, <name name-style="western"><surname>Wang</surname><given-names>C</given-names></name>, <name name-style="western"><surname>Killough</surname><given-names>JR</given-names></name>, <name name-style="western"><surname>Lewis</surname><given-names>SD</given-names></name>, <name name-style="western"><surname>Horwitz</surname><given-names>LR</given-names></name>, <name name-style="western"><surname>Ferguson</surname><given-names>A</given-names></name>, <name name-style="western"><surname>Thompson</surname><given-names>KM</given-names></name>, <name name-style="western"><surname>Pendergrast</surname><given-names>PS</given-names></name>, <name name-style="western"><surname>McCauley</surname><given-names>TG</given-names></name>, <name name-style="western"><surname>Kurz</surname><given-names>M</given-names></name></person-group>. <article-title>2-Deoxy purine, 2-O-methyl pyrimidine (dRmY) aptamers as candidate therapeutics</article-title>. <source>Oligonucleotides</source>
<year>2006</year>; <volume>16</volume>:<fpage>337</fpage>-<lpage>51</lpage>; PMID:17155909; http://dx.doi.org/<pub-id pub-id-type="doi">10.1089/oli.2006.16.337</pub-id><?supplied-pmid 17155909?><pub-id pub-id-type="pmid">17155909</pub-id></mixed-citation></ref><ref id="cit0044"><label>44.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Waters</surname><given-names>EK</given-names></name>, <name name-style="western"><surname>Genga</surname><given-names>RM</given-names></name>, <name name-style="western"><surname>Schwartz</surname><given-names>MC</given-names></name>, <name name-style="western"><surname>Nelson</surname><given-names>JA</given-names></name>, <name name-style="western"><surname>Schaub</surname><given-names>RG</given-names></name>, <name name-style="western"><surname>Olson</surname><given-names>KA</given-names></name>, <name name-style="western"><surname>Kurz</surname><given-names>JC</given-names></name>, <name name-style="western"><surname>McGinness</surname><given-names>KE</given-names></name></person-group>. <article-title>Aptamer ARC19499 mediates a procoagulant hemostatic effect by inhibiting tissue factor pathway inhibitor</article-title>. <source>Blood</source>
<year>2011</year>; <volume>117</volume>:<fpage>5514</fpage>-<lpage>22</lpage>; PMID:21389323; http://dx.doi.org/<pub-id pub-id-type="doi">10.1182/blood-2010-10-311936</pub-id><?supplied-pmid 21389323?><pub-id pub-id-type="pmid">21389323</pub-id></mixed-citation></ref><ref id="cit0045"><label>45.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Chelliserrykattil</surname><given-names>J</given-names></name>, <name name-style="western"><surname>Ellington</surname><given-names>A</given-names></name></person-group>. <article-title>Evolution of a T7 RNA polymerase variant that transcribes 2&#8242;-O-methyl RNA</article-title>. <source>Nat Biotechnol</source>
<year>2004</year>; <volume>22</volume>:<fpage>1155</fpage>-<lpage>60</lpage>; PMID:15300257; http://dx.doi.org/<pub-id pub-id-type="doi">10.1038/nbt1001</pub-id><?supplied-pmid 15300257?><pub-id pub-id-type="pmid">15300257</pub-id></mixed-citation></ref><ref id="cit0046"><label>46.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Fa</surname><given-names>M</given-names></name>, <name name-style="western"><surname>Radeghieri</surname><given-names>A</given-names></name>, <name name-style="western"><surname>Henry</surname><given-names>AA</given-names></name>, <name name-style="western"><surname>Romesberg</surname><given-names>FE</given-names></name></person-group>. <article-title>Expanding the substrate repertoire of a DNA polymerase by directed evolution</article-title>. <source>J Am Chem Soc</source>
<year>2004</year>; <volume>126</volume>:<fpage>1748</fpage>-<lpage>54</lpage>; PMID:14871106; http://dx.doi.org/<pub-id pub-id-type="doi">10.1021/ja038525p</pub-id><?supplied-pmid 14871106?><pub-id pub-id-type="pmid">14871106</pub-id></mixed-citation></ref><ref id="cit0047"><label>47.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Siegmund</surname><given-names>V</given-names></name>, <name name-style="western"><surname>Santner</surname><given-names>T</given-names></name>, <name name-style="western"><surname>Micura</surname><given-names>R</given-names></name>, <name name-style="western"><surname>Marx</surname><given-names>A</given-names></name></person-group>. <article-title>Screening mutant libraries of T7 RNA polymerase for candidates with increased acceptance of 2&#8242;-modified nucleotides</article-title>. <source>Chem Commun</source>
<year>2012</year>; <volume>48</volume>:<fpage>9870</fpage>-<lpage>2</lpage>; PMID:22932771; http://dx.doi.org/<pub-id pub-id-type="doi">10.1039/c2cc35028a</pub-id><?supplied-pmid 22932771?><pub-id pub-id-type="pmid">22932771</pub-id></mixed-citation></ref><ref id="cit0048"><label>48.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Padilla</surname><given-names>R</given-names></name>, <name name-style="western"><surname>Sousa</surname><given-names>R</given-names></name></person-group>. <article-title>A Y639F/H784A T7 RNA polymerase double mutant displays superior properties for synthesizing RNAs with non&#8208;canonical NTPs</article-title>. <source>Nucleic Acids Res</source>
<year>2002</year>; <volume>30</volume>:<fpage>e138</fpage>-<lpage>e</lpage>; PMID:12490729; http://dx.doi.org/<pub-id pub-id-type="doi">10.1093/nar/gnf138</pub-id><?supplied-pmid 12490729?><pub-id pub-id-type="pmid">12490729</pub-id></mixed-citation></ref><ref id="cit0049"><label>49.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Wu</surname><given-names>Y</given-names></name>, <name name-style="western"><surname>Sefah</surname><given-names>K</given-names></name>, <name name-style="western"><surname>Liu</surname><given-names>H</given-names></name>, <name name-style="western"><surname>Wang</surname><given-names>R</given-names></name>, <name name-style="western"><surname>Tan</surname><given-names>W</given-names></name></person-group>. <article-title>DNA aptamer&#8211;micelle as an efficient detection/delivery vehicle toward cancer cells</article-title>. <source>Proc Natl Acad Sci</source>
<year>2010</year>; <volume>107</volume>:<fpage>5</fpage>-<lpage>10</lpage>; PMID:20080797; http://dx.doi.org/<pub-id pub-id-type="doi">10.1073/pnas.0909611107</pub-id><?supplied-pmid 20080797?><pub-id pub-id-type="pmid">20080797</pub-id></mixed-citation></ref><ref id="cit0050"><label>50.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Kato</surname><given-names>Y</given-names></name>, <name name-style="western"><surname>Minakawa</surname><given-names>N</given-names></name>, <name name-style="western"><surname>Komatsu</surname><given-names>Y</given-names></name>, <name name-style="western"><surname>Kamiya</surname><given-names>H</given-names></name>, <name name-style="western"><surname>Ogawa</surname><given-names>N</given-names></name>, <name name-style="western"><surname>Harashima</surname><given-names>H</given-names></name>, <name name-style="western"><surname>Matsuda</surname><given-names>A</given-names></name></person-group>. <article-title>New NTP analogs: the synthesis of 4&#8242;-thioUTP and 4&#8242;-thioCTP and their utility for SELEX</article-title>. <source>Nucleic Acids Res</source>
<year>2005</year>; <volume>33</volume>:<fpage>2942</fpage>-<lpage>51</lpage>; PMID:15914669; http://dx.doi.org/<pub-id pub-id-type="doi">10.1093/nar/gki578</pub-id><?supplied-pmid 15914669?><pub-id pub-id-type="pmid">15914669</pub-id></mixed-citation></ref><ref id="cit0051"><label>51.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Ferreira-Bravo</surname><given-names>IA</given-names></name>, <name name-style="western"><surname>Cozens</surname><given-names>C</given-names></name>, <name name-style="western"><surname>Holliger</surname><given-names>P</given-names></name>, <name name-style="western"><surname>DeStefano</surname><given-names>JJ</given-names></name></person-group>. <article-title>Selection of 2&#8242;-deoxy-2&#8242;-fluoroarabinonucleotide (FANA) aptamers that bind HIV-1 reverse transcriptase with picomolar affinity</article-title>. <source>Nucleic Acids Res</source>
<year>2015</year>; <volume>43</volume>:<fpage>9587</fpage>-<lpage>99</lpage>; PMID:26476448; http://dx.doi.org/<pub-id pub-id-type="doi">10.1093/nar/gkv1057</pub-id><?supplied-pmid 26476448?><pub-id pub-id-type="pmid">26476448</pub-id></mixed-citation></ref><ref id="cit0052"><label>52.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Pinheiro</surname><given-names>VB</given-names></name>, <name name-style="western"><surname>Taylor</surname><given-names>AI</given-names></name>, <name name-style="western"><surname>Cozens</surname><given-names>C</given-names></name>, <name name-style="western"><surname>Abramov</surname><given-names>M</given-names></name>, <name name-style="western"><surname>Renders</surname><given-names>M</given-names></name>, <name name-style="western"><surname>Zhang</surname><given-names>S</given-names></name>, <name name-style="western"><surname>Chaput</surname><given-names>JC</given-names></name>, <name name-style="western"><surname>Wengel</surname><given-names>J</given-names></name>, <name name-style="western"><surname>Peak-Chew</surname><given-names>S-Y</given-names></name>, <name name-style="western"><surname>McLaughlin</surname><given-names>SH</given-names></name></person-group>. <article-title>Synthetic genetic polymers capable of heredity and evolution</article-title>. <source>Science</source>
<year>2012</year>; <volume>336</volume>:<fpage>341</fpage>-<lpage>4</lpage>; PMID:22517858; http://dx.doi.org/<pub-id pub-id-type="doi">10.1126/science.1217622</pub-id><?supplied-pmid 22517858?><pub-id pub-id-type="pmid">22517858</pub-id></mixed-citation></ref><ref id="cit0053"><label>53.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Yu</surname><given-names>H</given-names></name>, <name name-style="western"><surname>Zhang</surname><given-names>S</given-names></name>, <name name-style="western"><surname>Chaput</surname><given-names>JC</given-names></name></person-group>. <article-title>Darwinian evolution of an alternative genetic system provides support for TNA as an RNA progenitor</article-title>. <source>Nat Chem</source>
<year>2012</year>; <volume>4</volume>:<fpage>183</fpage>-<lpage>7</lpage>; PMID:22354431; http://dx.doi.org/<pub-id pub-id-type="doi">10.1038/nchem.1241</pub-id><?supplied-pmid 22354431?><pub-id pub-id-type="pmid">22354431</pub-id></mixed-citation></ref><ref id="cit0054"><label>54.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Yu</surname><given-names>H</given-names></name>, <name name-style="western"><surname>Zhang</surname><given-names>S</given-names></name>, <name name-style="western"><surname>Dunn</surname><given-names>MR</given-names></name>, <name name-style="western"><surname>Chaput</surname><given-names>JC</given-names></name></person-group>. <article-title>An efficient and faithful in vitro replication system for threose nucleic acid</article-title>. <source>J Am Chem Soc</source>
<year>2013</year>; <volume>135</volume>:<fpage>3583</fpage>-<lpage>91</lpage>; PMID:23432469; http://dx.doi.org/<pub-id pub-id-type="doi">10.1021/ja3118703</pub-id><?supplied-pmid 23432469?><pub-id pub-id-type="pmid">23432469</pub-id></mixed-citation></ref><ref id="cit0055"><label>55.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Larsen</surname><given-names>AC</given-names></name>, <name name-style="western"><surname>Dunn</surname><given-names>MR</given-names></name>, <name name-style="western"><surname>Hatch</surname><given-names>A</given-names></name>, <name name-style="western"><surname>Sau</surname><given-names>SP</given-names></name>, <name name-style="western"><surname>Youngbull</surname><given-names>C</given-names></name>, <name name-style="western"><surname>Chaput</surname><given-names>JC</given-names></name></person-group>. <article-title>A general strategy for expanding polymerase function by droplet microfluidics</article-title>. <source>Nat Commun</source>
<year>2016</year>; <volume>7</volume>:<fpage>11235</fpage>; PMID:27044725; http://dx.doi.org/<pub-id pub-id-type="doi">10.1038/ncomms11235</pub-id><?supplied-pmid 27044725?><pub-id pub-id-type="pmid">27044725</pub-id></mixed-citation></ref><ref id="cit0056"><label>56.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Veedu</surname><given-names>RN</given-names></name>, <name name-style="western"><surname>Vester</surname><given-names>B</given-names></name>, <name name-style="western"><surname>Wengel</surname><given-names>J</given-names></name></person-group>. <article-title>In vitro incorporation of LNA nucleotides</article-title>. <source>Nucleosides Nucleotides Nucleic Acids</source>
<year>2007</year>; <volume>26</volume>:<fpage>1207</fpage>-<lpage>10</lpage>; PMID:18058567; http://dx.doi.org/<pub-id pub-id-type="doi">10.1080/15257770701527844</pub-id><?supplied-pmid 18058567?><pub-id pub-id-type="pmid">18058567</pub-id></mixed-citation></ref><ref id="cit0057"><label>57.</label><mixed-citation publication-type="confproc"><person-group person-group-type="author"><name name-style="western"><surname>Veedu</surname><given-names>RN</given-names></name>, <name name-style="western"><surname>Vester</surname><given-names>B</given-names></name>, <name name-style="western"><surname>Wengel</surname><given-names>J</given-names></name></person-group>
<source>Novel applications of locked nucleic acids</source>. <conf-name>Nucleic Acids Symp Ser</conf-name>: <conf-sponsor>Oxford Univ Press</conf-sponsor>, <year>2007</year>; 51(1):29-30; PMID:18029570; http://dx.doi.org/17315250<pub-id pub-id-type="doi">10.1093/nass/nrm015</pub-id></mixed-citation></ref><ref id="cit0058"><label>58.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Veedu</surname><given-names>RN</given-names></name>, <name name-style="western"><surname>Vester</surname><given-names>B</given-names></name>, <name name-style="western"><surname>Wengel</surname><given-names>J</given-names></name></person-group>. <article-title>Enzymatic incorporation of LNA nucleotides into DNA strands</article-title>. <source>ChemBioChem</source>
<year>2007</year>; <volume>8</volume>:<fpage>490</fpage>-<lpage>2</lpage>; PMID:17315250; http://dx.doi.org/<pub-id pub-id-type="doi">10.1002/cbic.200600501</pub-id><?supplied-pmid 17315250?><pub-id pub-id-type="pmid">17315250</pub-id></mixed-citation></ref><ref id="cit0059"><label>59.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Veedu</surname><given-names>RN</given-names></name>, <name name-style="western"><surname>Vester</surname><given-names>B</given-names></name>, <name name-style="western"><surname>Wengel</surname><given-names>J</given-names></name></person-group>. <article-title>Polymerase chain reaction and transcription using locked nucleic acid nucleotide triphosphates</article-title>. <source>J Am Chem Soc</source>
<year>2008</year>; <volume>130</volume>:<fpage>8124</fpage>-<lpage>5</lpage>; PMID:18533656; http://dx.doi.org/<pub-id pub-id-type="doi">10.1021/ja801389n</pub-id><?supplied-pmid 18533656?><pub-id pub-id-type="pmid">18533656</pub-id></mixed-citation></ref><ref id="cit0060"><label>60.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Veedu</surname><given-names>RN</given-names></name>, <name name-style="western"><surname>Vester</surname><given-names>B</given-names></name>, <name name-style="western"><surname>Wengel</surname><given-names>J</given-names></name></person-group>. <article-title>Efficient enzymatic synthesis of LNA-modified DNA duplexes using KOD DNA polymerase</article-title>. <source>Org Biomol Chem</source>
<year>2009</year>; <volume>7</volume>:<fpage>1404</fpage>-<lpage>9</lpage>; PMID:19300826; http://dx.doi.org/<pub-id pub-id-type="doi">10.1039/b819946a</pub-id><?supplied-pmid 19300826?><pub-id pub-id-type="pmid">19300826</pub-id></mixed-citation></ref><ref id="cit0061"><label>61.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Veedu</surname><given-names>RN</given-names></name>, <name name-style="western"><surname>Wengel</surname><given-names>J</given-names></name></person-group>. <article-title>Locked nucleic acid nucleoside triphosphates and polymerases: on the way towards evolution of LNA aptamers</article-title>. <source>Mol Biosyst</source>
<year>2009</year>; <volume>5</volume>:<fpage>787</fpage>-<lpage>92</lpage>; PMID:19603111; http://dx.doi.org/<pub-id pub-id-type="doi">10.1039/b905513b</pub-id><?supplied-pmid 19603111?><pub-id pub-id-type="pmid">19603111</pub-id></mixed-citation></ref><ref id="cit0062"><label>62.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Veedu</surname><given-names>RN</given-names></name>, <name name-style="western"><surname>Wengel</surname><given-names>J</given-names></name></person-group>. <article-title>Locked nucleic acids: promising nucleic acid analogs for therapeutic applications</article-title>. <source>Chem Biodivers</source>
<year>2010</year>; <volume>7</volume>:<fpage>536</fpage>-<lpage>42</lpage>; PMID:20232325; http://dx.doi.org/<pub-id pub-id-type="doi">10.1002/cbdv.200900343</pub-id><?supplied-pmid 20232325?><pub-id pub-id-type="pmid">20232325</pub-id></mixed-citation></ref><ref id="cit0063"><label>63.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Veedu</surname><given-names>RN</given-names></name>, <name name-style="western"><surname>Wengel</surname><given-names>J</given-names></name></person-group>. <article-title>Locked nucleic acid as a novel class of therapeutic agents</article-title>. <source>RNA Biol</source>
<year>2009</year>; <volume>6</volume>:<fpage>321</fpage>-<lpage>3</lpage>; PMID:19458498; http://dx.doi.org/<pub-id pub-id-type="doi">10.4161/rna.6.3.8807</pub-id><?supplied-pmid 19458498?><pub-id pub-id-type="pmid">19458498</pub-id></mixed-citation></ref><ref id="cit0064"><label>64.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Crouzier</surname><given-names>L</given-names></name>, <name name-style="western"><surname>Dubois</surname><given-names>C</given-names></name>, <name name-style="western"><surname>Edwards</surname><given-names>SL</given-names></name>, <name name-style="western"><surname>Lauridsen</surname><given-names>LH</given-names></name>, <name name-style="western"><surname>Wengel</surname><given-names>J</given-names></name>, <name name-style="western"><surname>Veedu</surname><given-names>RN</given-names></name></person-group>. <article-title>Efficient reverse transcription using locked nucleic acid nucleotides towards the evolution of nuclease resistant RNA aptamers</article-title>. <source>PLoS One</source>
<year>2012</year>; <volume>7</volume>:<fpage>e35990</fpage>; PMID:22558297; http://dx.doi.org/<pub-id pub-id-type="doi">10.1371/journal.pone.0035990</pub-id><?supplied-pmid 22558297?><pub-id pub-id-type="pmid">22558297</pub-id></mixed-citation></ref><ref id="cit0065"><label>65.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>H&#248;jland</surname><given-names>T</given-names></name>, <name name-style="western"><surname>Veedu</surname><given-names>RN</given-names></name>, <name name-style="western"><surname>Vester</surname><given-names>B</given-names></name>, <name name-style="western"><surname>Wengel</surname><given-names>J</given-names></name></person-group>. <article-title>Enzymatic synthesis of DNA strands containing &#945;-L-LNA (&#945;-L-configured locked nucleic acid) thymine nucleotides</article-title>. <source>Artif DNA PNA XNA</source>
<year>2012</year>; <volume>3</volume>:<fpage>14</fpage>-<lpage>21</lpage>; PMID:22679529; http://dx.doi.org/<pub-id pub-id-type="doi">10.4161/adna.19272</pub-id><?supplied-pmid 22679529?><pub-id pub-id-type="pmid">22679529</pub-id></mixed-citation></ref><ref id="cit0066"><label>66.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Johannsen</surname><given-names>MW</given-names></name>, <name name-style="western"><surname>Veedu</surname><given-names>RN</given-names></name>, <name name-style="western"><surname>Madsen</surname><given-names>AS</given-names></name>, <name name-style="western"><surname>Wengel</surname><given-names>J</given-names></name></person-group>. <article-title>Enzymatic polymerisation involving 2&#8242;-amino-LNA nucleotides</article-title>. <source>Bioorg Med Chem Lett</source>
<year>2012</year>; <volume>22</volume>:<fpage>3522</fpage>-<lpage>6</lpage>; PMID:22503454; http://dx.doi.org/<pub-id pub-id-type="doi">10.1016/j.bmcl.2012.03.073</pub-id><?supplied-pmid 22503454?><pub-id pub-id-type="pmid">22503454</pub-id></mixed-citation></ref><ref id="cit0067"><label>67.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Veedu</surname><given-names>RN</given-names></name>, <name name-style="western"><surname>Vester</surname><given-names>B</given-names></name>, <name name-style="western"><surname>Wengel</surname><given-names>J</given-names></name></person-group>
<article-title>Polymerase directed incorporation studies of LNA-G nucleoside 5&#8242;-triphosphate and primer extension involving all four LNA nucleotides</article-title>. <source>New J Chem</source>
<year>2010</year>; <volume>34</volume>:<fpage>877</fpage>-<lpage>9</lpage>; http://dx.doi.org/<pub-id pub-id-type="doi">10.1039/b9nj00628a</pub-id></mixed-citation></ref><ref id="cit0068"><label>68.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Wheeler</surname><given-names>M</given-names></name>, <name name-style="western"><surname>Chardon</surname><given-names>A</given-names></name>, <name name-style="western"><surname>Goubet</surname><given-names>A</given-names></name>, <name name-style="western"><surname>Morihiro</surname><given-names>K</given-names></name>, <name name-style="western"><surname>Tsan</surname><given-names>SY</given-names></name>, <name name-style="western"><surname>Edwards</surname><given-names>SL</given-names></name>, <name name-style="western"><surname>Kodama</surname><given-names>T</given-names></name>, <name name-style="western"><surname>Obika</surname><given-names>S</given-names></name>, <name name-style="western"><surname>Veedu</surname><given-names>RN</given-names></name></person-group>. <article-title>Synthesis of selenomethylene-locked nucleic acid (SeLNA)-modified oligonucleotides by polymerases</article-title>. <source>Chem Commun</source>
<year>2012</year>; <volume>48</volume>:<fpage>11020</fpage>-<lpage>2</lpage>; PMID:23042489; http://dx.doi.org/<pub-id pub-id-type="doi">10.1039/c2cc36464f</pub-id><?supplied-pmid 23042489?><pub-id pub-id-type="pmid">23042489</pub-id></mixed-citation></ref><ref id="cit0069"><label>69.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Kuwahara</surname><given-names>M</given-names></name>, <name name-style="western"><surname>Obika</surname><given-names>S</given-names></name>, <name name-style="western"><surname>Nagashima</surname><given-names>J-i</given-names></name>, <name name-style="western"><surname>Ohta</surname><given-names>Y</given-names></name>, <name name-style="western"><surname>Suto</surname><given-names>Y</given-names></name>, <name name-style="western"><surname>Ozaki</surname><given-names>H</given-names></name>, <name name-style="western"><surname>Sawai</surname><given-names>H</given-names></name>, <name name-style="western"><surname>Imanishi</surname><given-names>T</given-names></name></person-group>. <article-title>Systematic analysis of enzymatic DNA polymerization using oligo-DNA templates and triphosphate analogs involving 2&#8242;, 4&#8242;-bridged nucleosides</article-title>. <source>Nucleic Acids Res</source>
<year>2008</year>; <volume>36</volume>:<fpage>4257</fpage>-<lpage>65</lpage>; PMID:18583360; http://dx.doi.org/<pub-id pub-id-type="doi">10.1093/nar/gkn404</pub-id><?supplied-pmid 18583360?><pub-id pub-id-type="pmid">18583360</pub-id></mixed-citation></ref><ref id="cit0070"><label>70.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Kasahara</surname><given-names>Y</given-names></name>, <name name-style="western"><surname>Irisawa</surname><given-names>Y</given-names></name>, <name name-style="western"><surname>Fujita</surname><given-names>H</given-names></name>, <name name-style="western"><surname>Yahara</surname><given-names>A</given-names></name>, <name name-style="western"><surname>Ozaki</surname><given-names>H</given-names></name>, <name name-style="western"><surname>Obika</surname><given-names>S</given-names></name>, <name name-style="western"><surname>Kuwahara</surname><given-names>M</given-names></name></person-group>. <article-title>Capillary electrophoresis&#8211;systematic evolution of ligands by exponential enrichment selection of base- and sugar-modified DNA aptamers: target binding dominated by 2&#8242;-O, 4&#8242;-C-methylene-bridged/locked nucleic acid primer</article-title>. <source>Anal Chem</source>
<year>2013</year>; <volume>85</volume>:<fpage>4961</fpage>-<lpage>7</lpage>; PMID:23662585; http://dx.doi.org/<pub-id pub-id-type="doi">10.1021/ac400058z</pub-id><?supplied-pmid 23662585?><pub-id pub-id-type="pmid">23662585</pub-id></mixed-citation></ref><ref id="cit0071"><label>71.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Klussmann</surname><given-names>S</given-names></name>, <name name-style="western"><surname>Nolte</surname><given-names>A</given-names></name>, <name name-style="western"><surname>Bald</surname><given-names>R</given-names></name>, <name name-style="western"><surname>Erdmann</surname><given-names>VA</given-names></name>, <name name-style="western"><surname>F&#252;rste</surname><given-names>JP</given-names></name></person-group>. <article-title>Mirror-image RNA that binds D-adenosine</article-title>. <source>Nat Biotechnol</source>
<year>1996</year>; <volume>14</volume>:<fpage>1112</fpage>-<lpage>5</lpage>; PMID:9631061; http://dx.doi.org/<pub-id pub-id-type="doi">10.1038/nbt0996-1112</pub-id><?supplied-pmid 9631061?><pub-id pub-id-type="pmid">9631061</pub-id></mixed-citation></ref><ref id="cit0072"><label>72.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Nolte</surname><given-names>A</given-names></name>, <name name-style="western"><surname>Klussmann</surname><given-names>S</given-names></name>, <name name-style="western"><surname>Bald</surname><given-names>R</given-names></name>, <name name-style="western"><surname>Erdmann</surname><given-names>VA</given-names></name>, <name name-style="western"><surname>F&#252;rste</surname><given-names>JP</given-names></name></person-group>. <article-title>Mirror-design of L-oligonucleotide ligands binding to L-arginine</article-title>. <source>Nat Biotechnol</source>
<year>1996</year>; <volume>14</volume>:<fpage>1116</fpage>-<lpage>9</lpage>; PMID:9631062; http://dx.doi.org/<pub-id pub-id-type="doi">10.1038/nbt0996-1116</pub-id><?supplied-pmid 9631062?><pub-id pub-id-type="pmid">9631062</pub-id></mixed-citation></ref><ref id="cit0073"><label>73.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Williams</surname><given-names>KP</given-names></name>, <name name-style="western"><surname>Liu</surname><given-names>X-H</given-names></name>, <name name-style="western"><surname>Schumacher</surname><given-names>TNM</given-names></name>, <name name-style="western"><surname>Lin</surname><given-names>HY</given-names></name>, <name name-style="western"><surname>Ausiello</surname><given-names>DA</given-names></name>, <name name-style="western"><surname>Kim</surname><given-names>PS</given-names></name>, <name name-style="western"><surname>Bartel</surname><given-names>DP</given-names></name></person-group>. <article-title>Bioactive and nuclease-resistant L-DNA ligand of vasopressin</article-title>. <source>Proc Natl Acad Sci</source>
<year>1997</year>; <volume>94</volume>:<fpage>11285</fpage>-<lpage>90</lpage>; PMID:9326601; http://dx.doi.org/<pub-id pub-id-type="doi">10.1073/pnas.94.21.11285</pub-id><?supplied-pmid 9326601?><pub-id pub-id-type="pmid">9326601</pub-id></mixed-citation></ref><ref id="cit0074"><label>74.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Purschke</surname><given-names>WG</given-names></name>, <name name-style="western"><surname>Radtke</surname><given-names>F</given-names></name>, <name name-style="western"><surname>Kleinjung</surname><given-names>F</given-names></name>, <name name-style="western"><surname>Klussmann</surname><given-names>S</given-names></name></person-group>. <article-title>A DNA Spiegelmer to staphylococcal enterotoxin B</article-title>. <source>Nucleic Acids Res</source>
<year>2003</year>; <volume>31</volume>:<fpage>3027</fpage>-<lpage>32</lpage>; PMID:12799428; http://dx.doi.org/<pub-id pub-id-type="doi">10.1093/nar/gkg413</pub-id><?supplied-pmid 12799428?><pub-id pub-id-type="pmid">12799428</pub-id></mixed-citation></ref><ref id="cit0075"><label>75.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Vater</surname><given-names>A</given-names></name>, <name name-style="western"><surname>Jarosch</surname><given-names>F</given-names></name>, <name name-style="western"><surname>Buchner</surname><given-names>K</given-names></name>, <name name-style="western"><surname>Klussmann</surname><given-names>S</given-names></name></person-group>. <article-title>Short bioactive Spiegelmers to migraine&#8208;associated calcitonin gene&#8208;related peptide rapidly identified by a novel approach: Tailored&#8208;SELEX</article-title>. <source>Nucleic Acids Res</source>
<year>2003</year>; <volume>31</volume>:<fpage>e130</fpage>-<lpage>e</lpage>; PMID:14576330; http://dx.doi.org/<pub-id pub-id-type="doi">10.1093/nar/gng130</pub-id><?supplied-pmid 14576330?><pub-id pub-id-type="pmid">14576330</pub-id></mixed-citation></ref><ref id="cit0076"><label>76.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Eulberg</surname><given-names>D</given-names></name>, <name name-style="western"><surname>Buchner</surname><given-names>K</given-names></name>, <name name-style="western"><surname>Maasch</surname><given-names>C</given-names></name>, <name name-style="western"><surname>Klussmann</surname><given-names>S</given-names></name></person-group>. <article-title>Development of an automated in vitro selection protocol to obtain RNA-based aptamers: identification of a biostable substance P antagonist</article-title>. <source>Nucleic Acids Res</source>
<year>2005</year>; <volume>33</volume>:<fpage>e45</fpage>-<lpage>e</lpage>; PMID:15745995; http://dx.doi.org/<pub-id pub-id-type="doi">10.1093/nar/gni044</pub-id><?supplied-pmid 15745995?><pub-id pub-id-type="pmid">15745995</pub-id></mixed-citation></ref><ref id="cit0077"><label>77.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Faulhammer</surname><given-names>D</given-names></name>, <name name-style="western"><surname>Eschgaller</surname><given-names>B</given-names></name>, <name name-style="western"><surname>Stark</surname><given-names>S</given-names></name>, <name name-style="western"><surname>Burgstaller</surname><given-names>P</given-names></name>, <name name-style="western"><surname>Englberger</surname><given-names>W</given-names></name>, <name name-style="western"><surname>Erfurth</surname><given-names>J</given-names></name>, <name name-style="western"><surname>Kleinjung</surname><given-names>F</given-names></name>, <name name-style="western"><surname>Rupp</surname><given-names>J</given-names></name>, <name name-style="western"><surname>Vulcu</surname><given-names>SD</given-names></name>, <name name-style="western"><surname>Schroder</surname><given-names>W</given-names></name></person-group>. <article-title>Biostable aptamers with antagonistic properties to the neuropeptide nociceptin/orphanin FQ</article-title>. <source>RNA</source>
<year>2004</year>; <volume>10</volume>:<fpage>516</fpage>-<lpage>27</lpage>; PMID:14970396; http://dx.doi.org/<pub-id pub-id-type="doi">10.1261/rna.5186504</pub-id><?supplied-pmid 14970396?><pub-id pub-id-type="pmid">14970396</pub-id></mixed-citation></ref><ref id="cit0078"><label>78.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Leva</surname><given-names>S</given-names></name>, <name name-style="western"><surname>Lichte</surname><given-names>A</given-names></name>, <name name-style="western"><surname>Burmeister</surname><given-names>J</given-names></name>, <name name-style="western"><surname>Muhn</surname><given-names>P</given-names></name>, <name name-style="western"><surname>Jahnke</surname><given-names>B</given-names></name>, <name name-style="western"><surname>Fesser</surname><given-names>D</given-names></name>, <name name-style="western"><surname>Erfurth</surname><given-names>J</given-names></name>, <name name-style="western"><surname>Burgstaller</surname><given-names>P</given-names></name>, <name name-style="western"><surname>Klussmann</surname><given-names>S</given-names></name></person-group>. <article-title>GnRH binding RNA and DNA Spiegelmers: a novel approach toward GnRH antagonism</article-title>. <source>Chem Biol</source>
<year>2002</year>; <volume>9</volume>:<fpage>351</fpage>-<lpage>9</lpage>; PMID:11927260; http://dx.doi.org/<pub-id pub-id-type="doi">10.1016/S1074-5521(02)00111-4</pub-id><?supplied-pmid 11927260?><pub-id pub-id-type="pmid">11927260</pub-id></mixed-citation></ref><ref id="cit0079"><label>79.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Jarosch</surname><given-names>F</given-names></name>, <name name-style="western"><surname>Buchner</surname><given-names>K</given-names></name>, <name name-style="western"><surname>Klussmann</surname><given-names>S</given-names></name></person-group>. <article-title>In vitro selection using a dual RNA library that allows primerless selection</article-title>. <source>Nucleic Acids Res</source>
<year>2006</year>; <volume>34</volume>:<fpage>e86</fpage>-<lpage>e</lpage>; PMID:16855281; http://dx.doi.org/<pub-id pub-id-type="doi">10.1093/nar/gkl463</pub-id><?supplied-pmid 16855281?><pub-id pub-id-type="pmid">16855281</pub-id></mixed-citation></ref><ref id="cit0080"><label>80.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Helmling</surname><given-names>S</given-names></name>, <name name-style="western"><surname>Maasch</surname><given-names>C</given-names></name>, <name name-style="western"><surname>Eulberg</surname><given-names>D</given-names></name>, <name name-style="western"><surname>Buchner</surname><given-names>K</given-names></name>, <name name-style="western"><surname>Schr&#246;der</surname><given-names>W</given-names></name>, <name name-style="western"><surname>Lange</surname><given-names>C</given-names></name>, <name name-style="western"><surname>Vonhoff</surname><given-names>S</given-names></name>, <name name-style="western"><surname>Wlotzka</surname><given-names>B</given-names></name>, <name name-style="western"><surname>Tsch&#246;p</surname><given-names>MH</given-names></name>, <name name-style="western"><surname>Rosewicz</surname><given-names>S</given-names></name></person-group>. <article-title>Inhibition of ghrelin action in vitro and in vivo by an RNA-Spiegelmer</article-title>. <source>Proc Natl Acad Sci U S A</source>
<year>2004</year>; <volume>101</volume>:<fpage>13174</fpage>-<lpage>9</lpage>; PMID:15329412; http://dx.doi.org/<pub-id pub-id-type="doi">10.1073/pnas.0404175101</pub-id><?supplied-pmid 15329412?><pub-id pub-id-type="pmid">15329412</pub-id></mixed-citation></ref><ref id="cit0081"><label>81.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Sundaram</surname><given-names>P</given-names></name>, <name name-style="western"><surname>Kurniawan</surname><given-names>H</given-names></name>, <name name-style="western"><surname>Byrne</surname><given-names>ME</given-names></name>, <name name-style="western"><surname>Wower</surname><given-names>J</given-names></name></person-group>. <article-title>Therapeutic RNA aptamers in clinical trials</article-title>. <source>Eur J Pharm Sci</source>
<year>2013</year>; <volume>48</volume>:<fpage>259</fpage>-<lpage>71</lpage>; PMID:23142634; http://dx.doi.org/<pub-id pub-id-type="doi">10.1016/j.ejps.2012.10.014</pub-id><?supplied-pmid 23142634?><pub-id pub-id-type="pmid">23142634</pub-id></mixed-citation></ref><ref id="cit0082"><label>82.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><collab>2016 NPA</collab></person-group>
<article-title>NOXXON Pharma AG</article-title>
<year>2016</year>.</mixed-citation></ref><ref id="cit0083"><label>83.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Yatime</surname><given-names>L</given-names></name>, <name name-style="western"><surname>Maasch</surname><given-names>C</given-names></name>, <name name-style="western"><surname>Hoehlig</surname><given-names>K</given-names></name>, <name name-style="western"><surname>Klussmann</surname><given-names>S</given-names></name>, <name name-style="western"><surname>Andersen</surname><given-names>GR</given-names></name>, <name name-style="western"><surname>Vater</surname><given-names>A</given-names></name></person-group>. <article-title>Structural basis for the targeting of complement anaphylatoxin C5a using a mixed L-RNA/L-DNA aptamer</article-title>. <source>Nat Commun</source>
<year>2015</year>; <volume>6</volume>:<fpage>6481</fpage>; PMID:25901944; http://dx.doi.org/<pub-id pub-id-type="doi">10.1038/ncomms7481</pub-id><?supplied-pmid 25901944?><pub-id pub-id-type="pmid">25901944</pub-id></mixed-citation></ref><ref id="cit0084"><label>84.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Wang</surname><given-names>Z</given-names></name>, <name name-style="western"><surname>Xu</surname><given-names>W</given-names></name>, <name name-style="western"><surname>Liu</surname><given-names>L</given-names></name>, <name name-style="western"><surname>Zhu</surname><given-names>TF</given-names></name></person-group>. <article-title>A synthetic molecular system capable of mirror-image genetic replication and transcription</article-title>. <source>Nat Chem</source>
<year>2016</year>; <volume>8</volume>:<fpage>698</fpage>-<lpage>704</lpage>; PMID:27325097; http://dx.doi.org/<pub-id pub-id-type="doi">10.1038/nchem.2517</pub-id><?supplied-pmid 27325097?><pub-id pub-id-type="pmid">27325097</pub-id></mixed-citation></ref><ref id="cit0085"><label>85.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Kuwahara</surname><given-names>M</given-names></name>, <name name-style="western"><surname>Nagashima</surname><given-names>J-i</given-names></name>, <name name-style="western"><surname>Hasegawa</surname><given-names>M</given-names></name>, <name name-style="western"><surname>Tamura</surname><given-names>T</given-names></name>, <name name-style="western"><surname>Kitagata</surname><given-names>R</given-names></name>, <name name-style="western"><surname>Hanawa</surname><given-names>K</given-names></name>, <name name-style="western"><surname>Hososhima</surname><given-names>S-i</given-names></name>, <name name-style="western"><surname>Kasamatsu</surname><given-names>T</given-names></name>, <name name-style="western"><surname>Ozaki</surname><given-names>H</given-names></name>, <name name-style="western"><surname>Sawai</surname><given-names>H</given-names></name></person-group>. <article-title>Systematic characterization of 2&#8242;-deoxynucleoside-5&#8242;-triphosphate analogs as substrates for DNA polymerases by polymerase chain reaction and kinetic studies on enzymatic production of modified DNA</article-title>. <source>Nucleic Acids Res</source>
<year>2006</year>; <volume>34</volume>:<fpage>5383</fpage>-<lpage>94</lpage>; PMID:17012278; http://dx.doi.org/<pub-id pub-id-type="doi">10.1093/nar/gkl637</pub-id><?supplied-pmid 17012278?><pub-id pub-id-type="pmid">17012278</pub-id></mixed-citation></ref><ref id="cit0086"><label>86.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>MacPherson</surname><given-names>IS</given-names></name>, <name name-style="western"><surname>Temme</surname><given-names>JS</given-names></name>, <name name-style="western"><surname>Habeshian</surname><given-names>S</given-names></name>, <name name-style="western"><surname>Felczak</surname><given-names>K</given-names></name>, <name name-style="western"><surname>Pankiewicz</surname><given-names>K</given-names></name>, <name name-style="western"><surname>Hedstrom</surname><given-names>L</given-names></name>, <name name-style="western"><surname>Krauss</surname><given-names>IJ</given-names></name></person-group>. <article-title>Multivalent glycocluster design through directed evolution</article-title>. <source>Angew Chem Int Ed</source>
<year>2011</year>; <volume>50</volume>:<fpage>11238</fpage>-<lpage>42</lpage>; PMID:22191092; http://dx.doi.org/<pub-id pub-id-type="doi">10.1002/anie.201105555</pub-id><?supplied-pmid 22191092?><pub-id pub-id-type="pmid">22191092</pub-id></mixed-citation></ref><ref id="cit0087"><label>87.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Temme</surname><given-names>JS</given-names></name>, <name name-style="western"><surname>MacPherson</surname><given-names>IS</given-names></name>, <name name-style="western"><surname>DeCourcey</surname><given-names>JF</given-names></name>, <name name-style="western"><surname>Krauss</surname><given-names>IJ</given-names></name></person-group>. <article-title>High temperature SELMA: Evolution of DNA-supported oligomannose clusters which are tightly recognized by HIV bnAb 2G12</article-title>. <source>J Am Chem Soc</source>
<year>2014</year>; <volume>136</volume>:<fpage>1726</fpage>-<lpage>9</lpage>; PMID:24446826; http://dx.doi.org/<pub-id pub-id-type="doi">10.1021/ja411212q</pub-id><?supplied-pmid 24446826?><pub-id pub-id-type="pmid">24446826</pub-id></mixed-citation></ref><ref id="cit0088"><label>88.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Tolle</surname><given-names>F</given-names></name>, <name name-style="western"><surname>Br&#228;ndle</surname><given-names>GM</given-names></name>, <name name-style="western"><surname>Matzner</surname><given-names>D</given-names></name>, <name name-style="western"><surname>Mayer</surname><given-names>G</given-names></name></person-group>. <article-title>A Versatile approach towards nucleobase&#8208;modified aptamers</article-title>. <source>Angew Chem Int Ed</source>
<year>2015</year>; <volume>54</volume>:<fpage>10971</fpage>-<lpage>4</lpage>; PMID:26224087; http://dx.doi.org/<pub-id pub-id-type="doi">10.1002/anie.201503652</pub-id><?supplied-pmid 26224087?><pub-id pub-id-type="pmid">26224087</pub-id></mixed-citation></ref><ref id="cit0089"><label>89.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Horiya</surname><given-names>S</given-names></name>, <name name-style="western"><surname>MacPherson</surname><given-names>IS</given-names></name>, <name name-style="western"><surname>Krauss</surname><given-names>IJ</given-names></name></person-group>. <article-title>Recent strategies targeting HIV glycans in vaccine design</article-title>. <source>Nat Chem Biol</source>
<year>2014</year>; <volume>10</volume>:<fpage>990</fpage>-<lpage>9</lpage>; PMID:25393493; http://dx.doi.org/<pub-id pub-id-type="doi">10.1038/nchembio.1685</pub-id><?supplied-pmid 25393493?><pub-id pub-id-type="pmid">25393493</pub-id></mixed-citation></ref><ref id="cit0090"><label>90.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Temme</surname><given-names>JS</given-names></name>, <name name-style="western"><surname>Drzyzga</surname><given-names>MG</given-names></name>, <name name-style="western"><surname>MacPherson</surname><given-names>IS</given-names></name>, <name name-style="western"><surname>Krauss</surname><given-names>IJ</given-names></name></person-group>. <article-title>Directed Evolution of 2G12&#8208;Targeted Nonamannose Glycoclusters by SELMA</article-title>. <source>Chem Eur J</source>
<year>2013</year>; <volume>19</volume>:<fpage>17291</fpage>-<lpage>5</lpage>; PMID:24227340; http://dx.doi.org/<pub-id pub-id-type="doi">10.1002/chem.201303848</pub-id><?supplied-pmid 24227340?><pub-id pub-id-type="pmid">24227340</pub-id></mixed-citation></ref><ref id="cit0091"><label>91.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Veedu</surname><given-names>R</given-names></name>, <name name-style="western"><surname>Burri</surname><given-names>H</given-names></name>, <name name-style="western"><surname>Kumar</surname><given-names>P</given-names></name>, <name name-style="western"><surname>Sharma</surname><given-names>P</given-names></name>, <name name-style="western"><surname>Hrdlicka</surname><given-names>P</given-names></name>, <name name-style="western"><surname>Vester</surname><given-names>B</given-names></name>, <name name-style="western"><surname>Wengel</surname><given-names>J</given-names></name></person-group>. <article-title>Polymerase-directed synthesis of C5-ethynyl locked nucleic acids</article-title>. <source>Bioorg Med Chem Lett</source>
<year>2010</year>; <volume>20</volume>:<fpage>6565</fpage>-<lpage>8</lpage>; PMID:20932755; http://dx.doi.org/<pub-id pub-id-type="doi">10.1016/j.bmcl.2010.09.044</pub-id><?supplied-pmid 20932755?><pub-id pub-id-type="pmid">20932755</pub-id></mixed-citation></ref><ref id="cit0092"><label>92.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Zhang</surname><given-names>L</given-names></name>, <name name-style="western"><surname>Yang</surname><given-names>Z</given-names></name>, <name name-style="western"><surname>Sefah</surname><given-names>K</given-names></name>, <name name-style="western"><surname>Bradley</surname><given-names>KM</given-names></name>, <name name-style="western"><surname>Hoshika</surname><given-names>S</given-names></name>, <name name-style="western"><surname>Kim</surname><given-names>M-J</given-names></name>, <name name-style="western"><surname>Kim</surname><given-names>H-J</given-names></name>, <name name-style="western"><surname>Zhu</surname><given-names>G</given-names></name>, <name name-style="western"><surname>Jim&#233;nez</surname><given-names>E</given-names></name>, <name name-style="western"><surname>Cansiz</surname><given-names>S</given-names></name></person-group>. <article-title>Evolution of functional six-nucleotide DNA</article-title>. <source>J Am Chem Soc</source>
<year>2015</year>; <volume>137</volume>:<fpage>6734</fpage>-<lpage>7</lpage>; PMID:25966323; http://dx.doi.org/<pub-id pub-id-type="doi">10.1021/jacs.5b02251</pub-id><?supplied-pmid 25966323?><pub-id pub-id-type="pmid">25966323</pub-id></mixed-citation></ref><ref id="cit0093"><label>93.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Thyer</surname><given-names>R</given-names></name>, <name name-style="western"><surname>Ellefson</surname><given-names>J</given-names></name></person-group>. <article-title>Synthetic biology: New letters for life's alphabet</article-title>. <source>Nature</source>
<year>2014</year>; <volume>509</volume>:<fpage>291</fpage>-<lpage>2</lpage>; PMID:24805244; http://dx.doi.org/<pub-id pub-id-type="doi">10.1038/nature13335</pub-id><?supplied-pmid 24805244?><pub-id pub-id-type="pmid">24805244</pub-id></mixed-citation></ref><ref id="cit0094"><label>94.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Sefah</surname><given-names>K</given-names></name>, <name name-style="western"><surname>Yang</surname><given-names>Z</given-names></name>, <name name-style="western"><surname>Bradley</surname><given-names>KM</given-names></name>, <name name-style="western"><surname>Hoshika</surname><given-names>S</given-names></name>, <name name-style="western"><surname>Jim&#233;nez</surname><given-names>E</given-names></name>, <name name-style="western"><surname>Zhang</surname><given-names>L</given-names></name>, <name name-style="western"><surname>Zhu</surname><given-names>G</given-names></name>, <name name-style="western"><surname>Shanker</surname><given-names>S</given-names></name>, <name name-style="western"><surname>Yu</surname><given-names>F</given-names></name>, <name name-style="western"><surname>Turek</surname><given-names>D</given-names></name></person-group>. <article-title>In vitro selection with artificial expanded genetic information systems</article-title>. <source>Proc Natl Acad Sci</source>
<year>2014</year>; <volume>111</volume>:<fpage>1449</fpage>-<lpage>54</lpage>; PMID:24379378; http://dx.doi.org/<pub-id pub-id-type="doi">10.1073/pnas.1311778111</pub-id><?supplied-pmid 24379378?><pub-id pub-id-type="pmid">24379378</pub-id></mixed-citation></ref><ref id="cit0095"><label>95.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Georgiadis</surname><given-names>MM</given-names></name>, <name name-style="western"><surname>Singh</surname><given-names>I</given-names></name>, <name name-style="western"><surname>Kellett</surname><given-names>WF</given-names></name>, <name name-style="western"><surname>Hoshika</surname><given-names>S</given-names></name>, <name name-style="western"><surname>Benner</surname><given-names>SA</given-names></name>, <name name-style="western"><surname>Richards</surname><given-names>NG</given-names></name></person-group>. <article-title>Structural basis for a six nucleotide genetic alphabet</article-title>. <source>J Am Chem Soc</source>
<year>2015</year>; <volume>137</volume>:<fpage>6947</fpage>-<lpage>55</lpage>; PMID:25961938; http://dx.doi.org/<pub-id pub-id-type="doi">10.1021/jacs.5b03482</pub-id><?supplied-pmid 25961938?><pub-id pub-id-type="pmid">25961938</pub-id></mixed-citation></ref><ref id="cit0096"><label>96.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Latham</surname><given-names>JA</given-names></name>, <name name-style="western"><surname>Johnson</surname><given-names>R</given-names></name>, <name name-style="western"><surname>Toole</surname><given-names>JJ</given-names></name></person-group>. <article-title>The application of a modified nucleotide in aptamer selection: novel thrombin aptamers containing-(1-pentynyl)-2&#8242;-deoxyuridine</article-title>. <source>Nucleic Acids Res</source>
<year>1994</year>; <volume>22</volume>:<fpage>2817</fpage>-<lpage>22</lpage>; PMID:7519769; http://dx.doi.org/<pub-id pub-id-type="doi">10.1093/nar/22.14.2817</pub-id><?supplied-pmid 7519769?><pub-id pub-id-type="pmid">7519769</pub-id></mixed-citation></ref><ref id="cit0097"><label>97.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Jensen</surname><given-names>KB</given-names></name>, <name name-style="western"><surname>Atkinson</surname><given-names>BL</given-names></name>, <name name-style="western"><surname>Willis</surname><given-names>MC</given-names></name>, <name name-style="western"><surname>Koch</surname><given-names>TH</given-names></name>, <name name-style="western"><surname>Gold</surname><given-names>L</given-names></name></person-group>. <article-title>Using in vitro selection to direct the covalent attachment of human immunodeficiency virus type 1 Rev protein to high-affinity RNA ligands</article-title>. <source>Proc Natl Acad Sci</source>
<year>1995</year>; <volume>92</volume>:<fpage>12220</fpage>-<lpage>4</lpage>; PMID:8618873; http://dx.doi.org/<pub-id pub-id-type="doi">10.1073/pnas.92.26.12220</pub-id><?supplied-pmid 8618873?><pub-id pub-id-type="pmid">8618873</pub-id></mixed-citation></ref><ref id="cit0098"><label>98.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Battersby</surname><given-names>TR</given-names></name>, <name name-style="western"><surname>Ang</surname><given-names>DN</given-names></name>, <name name-style="western"><surname>Burgstaller</surname><given-names>P</given-names></name>, <name name-style="western"><surname>Jurczyk</surname><given-names>SC</given-names></name>, <name name-style="western"><surname>Bowser</surname><given-names>MT</given-names></name>, <name name-style="western"><surname>Buchanan</surname><given-names>DD</given-names></name>, <name name-style="western"><surname>Kennedy</surname><given-names>RT</given-names></name>, <name name-style="western"><surname>Benner</surname><given-names>SA</given-names></name></person-group>. <article-title>Quantitative analysis of receptors for adenosine nucleotides obtained via in vitro selection from a library incorporating a cationic nucleotide analog</article-title>. <source>J Am Chem Soc</source>
<year>1999</year>; <volume>121</volume>:<fpage>9781</fpage>-<lpage>9</lpage>; PMID:11543572; http://dx.doi.org/<pub-id pub-id-type="doi">10.1021/ja9816436</pub-id><?supplied-pmid 11543572?><pub-id pub-id-type="pmid">11543572</pub-id></mixed-citation></ref><ref id="cit0099"><label>99.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Vaish</surname><given-names>NK</given-names></name>, <name name-style="western"><surname>Larralde</surname><given-names>R</given-names></name>, <name name-style="western"><surname>Fraley</surname><given-names>AW</given-names></name>, <name name-style="western"><surname>Szostak</surname><given-names>JW</given-names></name>, <name name-style="western"><surname>McLaughlin</surname><given-names>LW</given-names></name></person-group>. <article-title>A novel, modification-dependent ATP-binding aptamer selected from an RNA library incorporating a cationic functionality</article-title>. <source>Biochemistry</source>
<year>2003</year>; <volume>42</volume>:<fpage>8842</fpage>-<lpage>51</lpage>; PMID:12873145; http://dx.doi.org/<pub-id pub-id-type="doi">10.1021/bi027354i</pub-id><?supplied-pmid 12873145?><pub-id pub-id-type="pmid">12873145</pub-id></mixed-citation></ref><ref id="cit0100"><label>100.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Shoji</surname><given-names>A</given-names></name>, <name name-style="western"><surname>Kuwahara</surname><given-names>M</given-names></name>, <name name-style="western"><surname>Ozaki</surname><given-names>H</given-names></name>, <name name-style="western"><surname>Sawai</surname><given-names>H</given-names></name></person-group>. <article-title>Modified DNA aptamer that binds the (R)-isomer of a thalidomide derivative with high enantioselectivity</article-title>. <source>J Am Chem Soc</source>
<year>2007</year>; <volume>129</volume>:<fpage>1456</fpage>-<lpage>64</lpage>; PMID:17263432; http://dx.doi.org/<pub-id pub-id-type="doi">10.1021/ja067098n</pub-id><?supplied-pmid 17263432?><pub-id pub-id-type="pmid">17263432</pub-id></mixed-citation></ref><ref id="cit0101"><label>101.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Imaizumi</surname><given-names>Y</given-names></name>, <name name-style="western"><surname>Kasahara</surname><given-names>Y</given-names></name>, <name name-style="western"><surname>Fujita</surname><given-names>H</given-names></name>, <name name-style="western"><surname>Kitadume</surname><given-names>S</given-names></name>, <name name-style="western"><surname>Ozaki</surname><given-names>H</given-names></name>, <name name-style="western"><surname>Endoh</surname><given-names>T</given-names></name>, <name name-style="western"><surname>Kuwahara</surname><given-names>M</given-names></name>, <name name-style="western"><surname>Sugimoto</surname><given-names>N</given-names></name></person-group>. <article-title>Efficacy of base-modification on target binding of small molecule DNA aptamers</article-title>. <source>J Am Chem Soc</source>
<year>2013</year>; <volume>135</volume>:<fpage>9412</fpage>-<lpage>9</lpage>; PMID:23734784; http://dx.doi.org/<pub-id pub-id-type="doi">10.1021/ja4012222</pub-id><?supplied-pmid 23734784?><pub-id pub-id-type="pmid">23734784</pub-id></mixed-citation></ref><ref id="cit0102"><label>102.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Li</surname><given-names>M</given-names></name>, <name name-style="western"><surname>Lin</surname><given-names>N</given-names></name>, <name name-style="western"><surname>Huang</surname><given-names>Z</given-names></name>, <name name-style="western"><surname>Du</surname><given-names>L</given-names></name>, <name name-style="western"><surname>Altier</surname><given-names>C</given-names></name>, <name name-style="western"><surname>Fang</surname><given-names>H</given-names></name>, <name name-style="western"><surname>Wang</surname><given-names>B</given-names></name></person-group>. <article-title>Selecting aptamers for a glycoprotein through the incorporation of the boronic acid moiety</article-title>. <source>J Am Chem Soc</source>
<year>2008</year>; <volume>130</volume>:<fpage>12636</fpage>-<lpage>8</lpage>; PMID:18763762; http://dx.doi.org/<pub-id pub-id-type="doi">10.1021/ja801510d</pub-id><?supplied-pmid 18763762?><pub-id pub-id-type="pmid">18763762</pub-id></mixed-citation></ref><ref id="cit0103"><label>103.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Vaught</surname><given-names>JD</given-names></name>, <name name-style="western"><surname>Bock</surname><given-names>C</given-names></name>, <name name-style="western"><surname>Carter</surname><given-names>J</given-names></name>, <name name-style="western"><surname>Fitzwater</surname><given-names>T</given-names></name>, <name name-style="western"><surname>Otis</surname><given-names>M</given-names></name>, <name name-style="western"><surname>Schneider</surname><given-names>D</given-names></name>, <name name-style="western"><surname>Rolando</surname><given-names>J</given-names></name>, <name name-style="western"><surname>Waugh</surname><given-names>S</given-names></name>, <name name-style="western"><surname>Wilcox</surname><given-names>SK</given-names></name>, <name name-style="western"><surname>Eaton</surname><given-names>BE</given-names></name></person-group>. <article-title>Expanding the chemistry of DNA for in vitro selection</article-title>. <source>J Am Chem Soc</source>
<year>2010</year>; <volume>132</volume>:<fpage>4141</fpage>-<lpage>51</lpage>; PMID:20201573; http://dx.doi.org/<pub-id pub-id-type="doi">10.1021/ja908035g</pub-id><?supplied-pmid 20201573?><pub-id pub-id-type="pmid">20201573</pub-id></mixed-citation></ref><ref id="cit0104"><label>104.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Santoro</surname><given-names>SW</given-names></name>, <name name-style="western"><surname>Joyce</surname><given-names>GF</given-names></name>, <name name-style="western"><surname>Sakthivel</surname><given-names>K</given-names></name>, <name name-style="western"><surname>Gramatikova</surname><given-names>S</given-names></name>, <name name-style="western"><surname>Barbas</surname><given-names>CF</given-names></name></person-group>. <article-title>RNA cleavage by a DNA enzyme with extended chemical functionality</article-title>. <source>J Am Chem Soc</source>
<year>2000</year>; <volume>122</volume>:<fpage>2433</fpage>-<lpage>9</lpage>; PMID:11543272; http://dx.doi.org/<pub-id pub-id-type="doi">10.1021/ja993688s</pub-id><?supplied-pmid 11543272?><pub-id pub-id-type="pmid">11543272</pub-id></mixed-citation></ref><ref id="cit0105"><label>105.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Kimoto</surname><given-names>M</given-names></name>, <name name-style="western"><surname>Yamashige</surname><given-names>R</given-names></name>, <name name-style="western"><surname>Matsunaga</surname><given-names>K-i</given-names></name>, <name name-style="western"><surname>Yokoyama</surname><given-names>S</given-names></name>, <name name-style="western"><surname>Hirao</surname><given-names>I</given-names></name></person-group>. <article-title>Generation of high-affinity DNA aptamers using an expanded genetic alphabet</article-title>. <source>Nat Biotechnol</source>
<year>2013</year>; <volume>31</volume>:<fpage>453</fpage>-<lpage>7</lpage>; PMID:23563318; http://dx.doi.org/<pub-id pub-id-type="doi">10.1038/nbt.2556</pub-id><?supplied-pmid 23563318?><pub-id pub-id-type="pmid">23563318</pub-id></mixed-citation></ref><ref id="cit0106"><label>106.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Hollenstein</surname><given-names>M</given-names></name>, <name name-style="western"><surname>Hipolito</surname><given-names>CJ</given-names></name>, <name name-style="western"><surname>Lam</surname><given-names>CH</given-names></name>, <name name-style="western"><surname>Perrin</surname><given-names>DM</given-names></name></person-group>. <article-title>Toward the combinatorial selection of chemically modified DNAzyme RNase A mimics active against all-RNA substrates</article-title>. <source>ACS Comb Sci</source>
<year>2013</year>; <volume>15</volume>:<fpage>174</fpage>-<lpage>82</lpage>; PMID:23485334; http://dx.doi.org/<pub-id pub-id-type="doi">10.1021/co3001378</pub-id><?supplied-pmid 23485334?><pub-id pub-id-type="pmid">23485334</pub-id></mixed-citation></ref><ref id="cit0107"><label>107.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Gold</surname><given-names>L</given-names></name>, <name name-style="western"><surname>Ayers</surname><given-names>D</given-names></name>, <name name-style="western"><surname>Bertino</surname><given-names>J</given-names></name>, <name name-style="western"><surname>Bock</surname><given-names>C</given-names></name>, <name name-style="western"><surname>Bock</surname><given-names>A</given-names></name>, <name name-style="western"><surname>Brody</surname><given-names>EN</given-names></name>, <name name-style="western"><surname>Carter</surname><given-names>J</given-names></name>, <name name-style="western"><surname>Dalby</surname><given-names>AB</given-names></name>, <name name-style="western"><surname>Eaton</surname><given-names>BE</given-names></name>, <name name-style="western"><surname>Fitzwater</surname><given-names>T</given-names></name></person-group>. <article-title>Aptamer-based multiplexed proteomic technology for biomarker discovery</article-title>. <source>PLoS One</source>
<year>2010</year>; <volume>5</volume>:<fpage>e15004</fpage>; PMID:21165148; http://dx.doi.org/<pub-id pub-id-type="doi">10.1371/journal.pone.0015004</pub-id><?supplied-pmid 21165148?><pub-id pub-id-type="pmid">21165148</pub-id></mixed-citation></ref><ref id="cit0108"><label>108.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Davies</surname><given-names>DR</given-names></name>, <name name-style="western"><surname>Gelinas</surname><given-names>AD</given-names></name>, <name name-style="western"><surname>Zhang</surname><given-names>C</given-names></name>, <name name-style="western"><surname>Rohloff</surname><given-names>JC</given-names></name>, <name name-style="western"><surname>Carter</surname><given-names>JD</given-names></name>, <name name-style="western"><surname>O'Connell</surname><given-names>D</given-names></name>, <name name-style="western"><surname>Waugh</surname><given-names>SM</given-names></name>, <name name-style="western"><surname>Wolk</surname><given-names>SK</given-names></name>, <name name-style="western"><surname>Mayfield</surname><given-names>WS</given-names></name>, <name name-style="western"><surname>Burgin</surname><given-names>AB</given-names></name></person-group>. <article-title>Unique motifs and hydrophobic interactions shape the binding of modified DNA ligands to protein targets</article-title>. <source>Proc Natl Acad Sci</source>
<year>2012</year>; <volume>109</volume>:<fpage>19971</fpage>-<lpage>6</lpage>; PMID:23139410; http://dx.doi.org/<pub-id pub-id-type="doi">10.1073/pnas.1213933109</pub-id><?supplied-pmid 23139410?><pub-id pub-id-type="pmid">23139410</pub-id></mixed-citation></ref><ref id="cit0109"><label>109.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Ochsner</surname><given-names>UA</given-names></name>, <name name-style="western"><surname>Katilius</surname><given-names>E</given-names></name>, <name name-style="western"><surname>Janjic</surname><given-names>N</given-names></name></person-group>. <article-title>Detection of Clostridium difficile toxins A, B and binary toxin with slow off-rate modified aptamers</article-title>. <source>Diagn Microbiol Infect Dis</source>
<year>2013</year>; <volume>76</volume>:<fpage>278</fpage>-<lpage>85</lpage>; PMID:23680240; http://dx.doi.org/<pub-id pub-id-type="doi">10.1016/j.diagmicrobio.2013.03.029</pub-id><?supplied-pmid 23680240?><pub-id pub-id-type="pmid">23680240</pub-id></mixed-citation></ref><ref id="cit0110"><label>110.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Jhaveri</surname><given-names>S</given-names></name>, <name name-style="western"><surname>Olwin</surname><given-names>B</given-names></name>, <name name-style="western"><surname>Ellington</surname><given-names>AD</given-names></name></person-group>. <article-title>In vitro selection of phosphorothiolated aptamers</article-title>. <source>Bioorg Med Chem Lett</source>
<year>1998</year>; <volume>8</volume>:<fpage>2285</fpage>-<lpage>90</lpage>; PMID:9873529; http://dx.doi.org/<pub-id pub-id-type="doi">10.1016/S0960-894X(98)00414-4</pub-id><?supplied-pmid 9873529?><pub-id pub-id-type="pmid">9873529</pub-id></mixed-citation></ref><ref id="cit0111"><label>111.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>King</surname><given-names>DJ</given-names></name>, <name name-style="western"><surname>Bassett</surname><given-names>SE</given-names></name>, <name name-style="western"><surname>Li</surname><given-names>X</given-names></name>, <name name-style="western"><surname>Fennewald</surname><given-names>SA</given-names></name>, <name name-style="western"><surname>Herzog</surname><given-names>NK</given-names></name>, <name name-style="western"><surname>Luxon</surname><given-names>BA</given-names></name>, <name name-style="western"><surname>Shope</surname><given-names>R</given-names></name>, <name name-style="western"><surname>Gorenstein</surname><given-names>DG</given-names></name></person-group>. <article-title>Combinatorial selection and binding of phosphorothioate aptamers targeting human NF-&#954;B RelA (p65) and p50</article-title>. <source>Biochemistry</source>
<year>2002</year>; <volume>41</volume>:<fpage>9696</fpage>-<lpage>706</lpage>; PMID:12135392; http://dx.doi.org/<pub-id pub-id-type="doi">10.1021/bi020220k</pub-id><?supplied-pmid 12135392?><pub-id pub-id-type="pmid">12135392</pub-id></mixed-citation></ref><ref id="cit0112"><label>112.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>King</surname><given-names>DJ</given-names></name>, <name name-style="western"><surname>Ventura</surname><given-names>DA</given-names></name>, <name name-style="western"><surname>Brasier</surname><given-names>AR</given-names></name>, <name name-style="western"><surname>Gorenstein</surname><given-names>DG</given-names></name></person-group>. <article-title>Novel combinatorial selection of phosphorothioate oligonucleotide aptamers</article-title>. <source>Biochemistry</source>
<year>1998</year>; <volume>37</volume>:<fpage>16489</fpage>-<lpage>93</lpage>; PMID:9843415; http://dx.doi.org/<pub-id pub-id-type="doi">10.1021/bi981780f</pub-id><?supplied-pmid 9843415?><pub-id pub-id-type="pmid">9843415</pub-id></mixed-citation></ref><ref id="cit0113"><label>113.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Lato</surname><given-names>SM</given-names></name>, <name name-style="western"><surname>Ozerova</surname><given-names>NDS</given-names></name>, <name name-style="western"><surname>He</surname><given-names>K</given-names></name>, <name name-style="western"><surname>Sergueeva</surname><given-names>Z</given-names></name>, <name name-style="western"><surname>Shaw</surname><given-names>BR</given-names></name>, <name name-style="western"><surname>Burke</surname><given-names>DH</given-names></name></person-group>. <article-title>Boron-containing aptamers to ATP</article-title>. <source>Nucleic Acids Res</source>
<year>2002</year>; <volume>30</volume>:<fpage>1401</fpage>-<lpage>7</lpage>; PMID:11884639; http://dx.doi.org/<pub-id pub-id-type="doi">10.1093/nar/30.6.1401</pub-id><?supplied-pmid 11884639?><pub-id pub-id-type="pmid">11884639</pub-id></mixed-citation></ref></ref-list></back></article>